β-Adrenoceptor Blocking Agents

  • B. N. C. Prichard
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 76)

Abstract

The idea of different adrenergic receptors originated with Langley in 1905. He suggested that the receptors contained inhibitory and excitatory receptor substances. Sir Henry Dale (1906) observed the next year that while the excitatory actions of adrenaline were blocked by ergot, the inhibitory ones were not, providing evidence for two types of adrenergic receptors. Then in 1948 Ahlquist published his now classical paper in the American Journal of Physiology where he studied the effect of six sympathetic stimulating drugs and revealed two patterns of response. He termed one pattern the α effects which included vasoconstriction, here adrenaline was most potent, followed by noradrenaline. Secondly there were β effects which included smooth muscle relaxation and cardiac stimulation. Isoprenaline was the most active here, adrenaline was third, and noradrenaline least effective (Ahlquist 1948). The adrenergic receptors have subsequently been further divided into α1, α2, ß 1 and ß 2 receptors (Lefkowitz 1976; Williams and Lefkowitz 1978; Lees 1981; Andersson 1982). The first report of ß adrenoceptor blocking activity came in 1958 when the properties of dichloroisoprenaline were discovered in animal experiments. This drug had powerful intrinsic sympathomimetic activity and while its importance as a pharmacological tool was recognized the therapeutic potential of this new approach was not (Moran and Perkins 1958; Powell and Slater 1958).

Keywords

Noradrenaline Catecholamine Cardiol Indomethacin Triglyceride 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aarons RD, Nies AS, Gal J, Hegstrand LR, Molinoff PB (1980) Elevation of ß-adrenergic receptor density in human lymphocytes after propranolol administration. J Clin Invest 65: 949–957PubMedGoogle Scholar
  2. Åblad B, Ervik M, Hallgren J, Johnsson G, Sölvell L (1972) Pharmacological effects and serum levels of orally administered alprenolol in man. Eur J Clin Pharmacol 5: 44–52Google Scholar
  3. Åblad B, Ljung B, Sannerstedt R (1976) Haemodynamic effects of ß-adrenoreceptor blockers in hypertension. Drugs 11 [Suppl 1]: 127–134PubMedGoogle Scholar
  4. Adam WR, Meagher EJ, Barter CE (1982) Labetalol, beta blockers and acute Deterioration of chronic airways obstruction. Clin Exp Hypertens A4 (8): 1419–1428Google Scholar
  5. Adolfsson L, Areskog NH; Furberg C, Granath A, Zetterquist S (1972) Synergistic effects of a new ß-adrenergic blocker ( Pindolol) and Isosorbide-dinitrate during exercise in patients with coronary insufficiency. Eur J Clin Pharmacol 5: 37–40Google Scholar
  6. Adolfsson L, Areskog NH, Furberg C, Johnsson G (1974) Effects of single doses of alprenolol and two cardioselective ß-blockers (H87/07 and H93/26) on exercise-induced angina pectoris. Eur J Clin Pharmacol 7: 111–118PubMedGoogle Scholar
  7. Aellig WH (1983) Clinical pharmacology of ß-adrenoceptor blocking drugs possessing partial agonist activity, with special reference to pindolol. J Cardiovasc Pharmacol 5: S16–S20PubMedGoogle Scholar
  8. Agarwal AK, Ahuja RC, Chandra M, Gupta NN, Hasan M (1976) A double-blind trial of penbutolol: a new beta-receptor blocking agent in the treatment of angina pectoris. J Int Med Res 4: 410–417PubMedGoogle Scholar
  9. Agostini A, Berfasconi C, Gerli GC, Luzzana M, Rossi-Bernardi L (1973) Oxygen affinity and electrolyte distribution of human blood: changes induced by propranolol. Science 182: 300–301Google Scholar
  10. Ahlmark G, Saetre H, Korsgren M (1974) Reduction of sudden deaths after myocardial infarction. Lancet 2: 1563PubMedGoogle Scholar
  11. Ahlmark G, Saetre H (1976) Long-term treatment with ß-blockers after myocardial infarction. Eur J Clin Pharmacol 10: 77–83PubMedGoogle Scholar
  12. Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153: 586–600PubMedGoogle Scholar
  13. Alcocer L, Aspe J, Arce E, Vieyra J (1982) The effect of carteolol, a new beta-blocker, on angina pectoris. Curr Ther Res 31 (1): 67–73Google Scholar
  14. Alcock SJ, Bond PA (1964) Observations on the toxicity of Alderlin (pronethalol) in laboratory animals. Proc Eur Soc Study Drug Toxicity 4: 30–39Google Scholar
  15. Alderman EL, Coltart DJ, Wettach GE, Harrison DC (1974) Coronary artery syndromes after sudden propranolol withdrawal. Ann Intern Med 81: 625–627PubMedGoogle Scholar
  16. Alderman EL, Davis RO, Crowley JJ, Lopes MG, Brooker JZ, Friedman JP, Graham AF, Matlof HJ, Harrison DC (1975) Dose response effectiveness of propranolol for the treatment of angina pectoris. Circulation 51: 964–975PubMedGoogle Scholar
  17. Alonso DR, Scheidt S, Post M, Killip L (1973) Pathophysiology of cardiogenic shock. Quantification of myocardial necrosis: clinical, pathologic and electrocardiographic correlations. Circulation 48: 588–596PubMedGoogle Scholar
  18. Alvan G, Von Bahr C, Seideman P, Sjoqvist F (1982) High plasma concentrations of betareceptor blocking drugs and deficient debrisoquine hydroxylation. Lancet 1: 333PubMedGoogle Scholar
  19. Ames RP, Hill P (1978) Raised serum lipid concentrations during diuretic treatment of hypertension: a study of predictive indexes. Clin Sci Mol Med 55: 311S–314SGoogle Scholar
  20. Amos HE, Brigden WD, McKerron RA (1975) Untoward effects associated with practolol: demonstration of antibody binding to epithelial tissue. Br Med J 1: 598–600PubMedGoogle Scholar
  21. Amsterdam EA, Gorlin R, Wolfson S (1969) Evaluation of long-term use of propranolol in angina pectoris. J Am Med Assoc 210: 103–106Google Scholar
  22. Anastassiades C (1982) Nifedipine and beta-blockade as a cause of cardiac failure. Br Med J 284 (6314): 506Google Scholar
  23. Anavekar SN, Louis WJ, Morgan TO, Doyle AE, Johnston CI (1975) The relationship of plasma levels of pindolol in hypertensive patients to effect on blood pressure, plasmarenin and plasma noradrenaline levels. Clin Exp Pharmacol Physiol 2: 203–212PubMedGoogle Scholar
  24. Andersson K-E (1982) Drugs blocking adrenoceptors. Acta Med Scand [Suppl] 665: 9–17Google Scholar
  25. Andersen MP, Bechsgaard P, Frederiksen J, Hansen DA, Jürgensen HJ, Nielsen B, Pedersen F, Pedersen-Bjergaard O, Rasmussen SL (1979) Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Lancet 2: 865–868PubMedGoogle Scholar
  26. Andren L, Hansson L, Bjorkman M (1982) Haemodynamic effects of noise exposure before and after bx-selective and nonselective b-adrenoceptor blockade in patients with essential hypertension. Clin Sci 61: 89s–91sGoogle Scholar
  27. Anonymous (1982) Long-term and short-term beta-blockade after myocardial infarction. Lancet 1: 1159–1161Google Scholar
  28. Anttila M, Arstila M, Pfeffer M, Tikkanen R, Vallinkoski V, Sundquist H (1976) Human pharmacokinetics of sotalol. Acta Pharmacol Toxicol 39: 118–28Google Scholar
  29. Apthorp GH, Chamberlain DA, Hayward GW (1964) The effects of sympathectomy on the electrocardiogram and effort tolerance in angina pectoris. Br Heart J 26: 218–226PubMedGoogle Scholar
  30. Aravanis C, Michaelides G (1970) Results of the use of a new beta-adrenergic blocker (LB46) in angina pectoris. Acta Cardiol 25: 501–509PubMedGoogle Scholar
  31. Areskog NH, Adolfsson L (1969) Effects of a cardioselective beta-adrenergic blocker (ICI 50172) on exercise in angina pectoris. Br Med J 2: 601–603PubMedGoogle Scholar
  32. Amman K, Ryden L (1982) Comparison of metoprolol and verapamil in the treatment of angina pectoris. Am J Cardiol 49: 821–827Google Scholar
  33. Arnold JMO, McDevitt DG (1982) Interpretation of isoprenaline dose-response curves in the presence of selective and nonselective ß–adrenoceptor blocking drugs. Br J Clin Pharmacol 13: 585 PGoogle Scholar
  34. Astrom H, Vallin H (1974) Effect of new beta-adrenergic blocking agent, ICI 66082, on exercise haemodynamics and airway resistance in angina pectoris. Br Heart J 36: 1194–1200PubMedGoogle Scholar
  35. Atkins JM, Blomqvist G, Cohen LS, Mitchell JH, Mullins CB (1971) Serial exercise studies in ischaemic heart disease (I.H.D.). Effects of placebo and ß-adrenergic blocking agents. Clin Res 19: 62Google Scholar
  36. Atterhog JH, Duner H, Pernow B (1976) Haemodynamic effect of pindolol with special reference to the resistance and capacitance vessels of the forearm. Acta Med Scand 199: 251–255PubMedGoogle Scholar
  37. Aubert A, Nyberg G, Slaastad R, Tjeldflaat L (1970) Prophylactic treatment of angina pectoris. A double-blind crossover comparison of alprenalol and pentanitrol. Br Med J 1: 203–206Google Scholar
  38. Baber NS, Lewis JA (1982) Confidence in results of beta-blocker postinfarction trials. Br Med J 284: 1749–1750Google Scholar
  39. Baber NS, Wainwright Evans D, Howitt G, Thomas M, Wilson C, Lewis JA, Dawes PM, Handler K, Tuson R (1980) Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy and Yugoslavia. Br Heart J 44: 96–100Google Scholar
  40. Bala-Subramanian VB, Bowles MJ, Davies AB, Raftery EB (1982) Calcium channel blockade as primary therapy for stable angina pectoris. Am J Cardiol 50: 1158–1163Google Scholar
  41. Barrett AM (1969) A comparison of the effect of (+) propranolol and (+) propranolol in anaesthetised dogs; ß-receptor blocking and haemodynamic action. J Pharmacol 21: 241–247Google Scholar
  42. Bassan MM, Weiler-Ravell D (1983) Effect of a twelve-hour hiatus in propranolol therapy on exercise tolerance in patients with angina pectoris. Am Heart J 105: 234–238PubMedGoogle Scholar
  43. Bassan M, Weiler-Ravell D, Shaley O (1982 b) The additive antianginal action of oral nifedipine in patients receiving propranolol. Magnitude and duration of effect. Circulation 66 (4): 710–716Google Scholar
  44. Bateman DN, Dean CR, Mucklow JC, Bulpitt CJ, Dollery CT (1979) Atenolol and chlorthalidone in combination for hypertension. Br J Clin Pharmacol 7: 357–363PubMedGoogle Scholar
  45. Battler A, Ross J, Slutsky R, Pflsterer M, Ashburn W, Froelicher V (1979) Improvement of exercise-induced left ventricular dysfunction with oral propranolol in patients with coronary heart disease. Am J Cardiol 44: 318–324PubMedGoogle Scholar
  46. Battock DJ, Alvarez H, Chidsey CA (1969) Effects of propranolol and isosorbide dinitrate on exercise performance and adrenergic activity in patients with angina pectoris. Circulation 39: 157–169PubMedGoogle Scholar
  47. Bauer JH, Brooks CS (1979) The long-term effect of propranolol therapy on renal function. Am J Med 66: 405–410PubMedGoogle Scholar
  48. Bauer JH, Brooks CS, Weinstein I, Wilcox HH, Heimberg M, Burch RN, Barkley R (1981) Effects of diuretic and propranolol on plasma lipoprotein lipids. Clin Pharmacol Ther 30: 35–43PubMedGoogle Scholar
  49. Becker LC, Fortuin NH, Pitt B (1971) Effect of ischaemic and antianginal drugs on the distribution of radioactive microspheres in the canine left ventricle. Circ Res 28: 263–269PubMedGoogle Scholar
  50. Beeley L, Talbot J (1979) Beta-blocker withdrawal syndrome? Lancet 1: 387PubMedGoogle Scholar
  51. Beinart IW, Pearson RM, Cramp DG, Havard CWH (1979) The effect of metoprolol on plasma lipids. Postgrad Med J 55: 709–711PubMedGoogle Scholar
  52. Belton P, O’Dwyer WF, Carmody M, Donohoe J (1980) Propranolol associated hypoglycaemia in non-diabetics. Ir Med J 73: 173PubMedGoogle Scholar
  53. Benaim ME (1972) Asystole after verapamil. Br Med J 2: 169PubMedGoogle Scholar
  54. Benfield GFA, Hunter KR (1982) Oxprenolol, methyldopa and lipids in diabetes mellitus. Br J Clin Pharmacol 13: 219–222PubMedGoogle Scholar
  55. Bennet D, Balcon R, Hoy J, Sowton E (1970) Haemodynamic effects of dextropranolol in acute myocardial infarction. Thorax 25: 86–88PubMedGoogle Scholar
  56. Bennett DH (1982) Acute prolongation of myocardial refractoriness by sotalol. Br Heart J 47 (6): 521–526PubMedGoogle Scholar
  57. Berdeaux A, Da Costa CP, Gamier M, Boissier J-R, Giudicelli J-F (1978) Beta adrenergic blockade, regional left ventricular blood flow and ST-segment elevation in canine experimental myocardial ischaemia. J Pharmacol Exp Ther 205: 646–656PubMedGoogle Scholar
  58. Besterman EMM, Spencer M (1979) Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients. Br J Clin Pharmacol 8 [Suppl 2]205s–209sGoogle Scholar
  59. Bett JH (1968) Hypotension after oral propranolol. Lancet 1: 302Google Scholar
  60. Betts TA, Alford C (1983) Beta blocking drugs and sleep. A controlled trial. Drugs 25 [Suppl 2]: 268–272Google Scholar
  61. Beumer HM (1974) Adverse effects of ß-adrenergic receptor blocking drugs on respiratory function. Drugs 7: 130–138PubMedGoogle Scholar
  62. Bhat (1982) Beta-blocker heart attack trial research group 1. Mortality results. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 247: 1707–1714Google Scholar
  63. Bianchetti MG, Boehringer K, Weidmann P, Link L, Schiffl H, Ziegler WH (1982) Acute effects of prizidolol on blood pressure, heart rate, catecholamines, renin and aldosterone in essential hypertension. Eur J Clin Pharmacol 23: 289–296PubMedGoogle Scholar
  64. Bianchi C, Lucchelli PE, Starcich R (1969) Beta blockade and angina pectoris: a controlled multi-centre clinical trial. Pharmacologia Clinica 1: 161–167Google Scholar
  65. Bjorntorp P (1967) The treatment of angina pectoris with a new beta–receptor blocking agent (H56/28). Acta Med Scand 182: 285–291PubMedGoogle Scholar
  66. Bjorntorp P (1968) Treatment of angina pectoris with beta-adrenergic blockade, mode of action. Acta Med Scand 184: 259–262PubMedGoogle Scholar
  67. Bjorntorp P (1971) Treatment of angina pectoris with beta-receptor blocking agents. Effect of long-term treatment with sustained release tablets. Acta Med Scand 189: 299–301PubMedGoogle Scholar
  68. Black JW, Stephenson JS (1962) Pharmacology of a new adrenergic beta–receptor blocking compound ( Nethalide ). Lancet 2: 311–314Google Scholar
  69. Boakes AJ, Prichard BNC (1973) The effect of AH 5158, pindolol, propranolol and d-propranolol on acute exercise tolerance in angina pectoris. Br J Pharmacol 47: 673–674 PGoogle Scholar
  70. Bobik A, Jennings GL, Korner PI, Ashley P, Jackman G (1979) Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise. Br J Clin Pharmacol 7: 545–549PubMedGoogle Scholar
  71. Bodem G, Grieser H, Eichelbaum M, Gugler R (1974) Pharmacokinetics of practolol in renal failure. Eur J Clin Pharmacol 7: 249–252PubMedGoogle Scholar
  72. Bodin N-O, Borg K-O, Johansson R, Obianwu H, Svensson R (1974) Absorption, distribution and excretion of alprenolol in man, dog and rat. Acta Pharmacol Toxicol 35: 261–269Google Scholar
  73. Bolli G, De Feo P, Compagnucci P, Cartechini MG, Angeletti G, Santeusanio F, Brunetti P (1982) Important role of adrenergic mechanisms in acute glucose counterregulation following insulin-induced hypoglycaemia in type I diabetes. Evidence for an effect mediated by beta-adrenoreceptors. Diabetes 31: 641–647Google Scholar
  74. Bolli P, Bühler FR, Raeder EA, Amann FW, Meier M, Rogg H, Burckhardt D (1981) Lack of beta-adrenoreceptor hypersensitivity after abrupt withdrawal of long-term therapy with oxprenolol. Circulation 64 (6): 1130–1134PubMedGoogle Scholar
  75. Booth RJ, Bullock JY, Wilson JD (1980) Antinuclear antibodies during acebutolol therapy. Br J Clin Pharmacol May 9 (5): 515–7Google Scholar
  76. Booth RJ, Wilson JD, Bullock JY (1982) Adrenergic receptor blockers and antinuclear antibodies in hypertension. Clin Pharmacol Ther 31 (5): 555–558PubMedGoogle Scholar
  77. Boothby CB, Garrard CS, Pickering D (1972) Verapamil in cardiac arrhythmias. Br Med J 11: 349Google Scholar
  78. Borg K-O, Carlsson E, Hoffman K-J, Jonsson T-E, Thorin H, Wallin B (1975) Metabolism of metoprolol - (3H) in man, the dog and the rat. Acta Pharmacol Toxicol 36 [Suppl V]: 125–135Google Scholar
  79. Boudoulas H, Lewis RP, Kates RE, Dalamangas G (1977) Hypersensitivity to adrenergic stimulation after propranolol withdrawal in normal subjects. Ann Intern Med 87: 433–436PubMedGoogle Scholar
  80. Boudoulas H, Lewis RP, Rittgers SE, Leier VC, Vasko JS (1979) Increased diastolic time: a possible important factor in the beneficial effect of propranolol in patients with coronary artery disease. J Cardiovasc Pharmacol 1: 503–513PubMedGoogle Scholar
  81. Boudoulas H, Dervengas S, Fulkerson PK, Bush CA, Lewis RP (1981) Effect of heart rate on diastolic time and left ventricular performance in patients with atrial fibrillation. In: Dietrich (ed) Non-invasive cardiovascular diagnosis, 2nd edn. Wright-PSG, LittletonGoogle Scholar
  82. Brailovsky D (1974) Timolol Maleate (MK-950). A new beta-blocking agent for the prophylactic management of angina pectoris. A multicenre, multinational, cooperative trial. In: Magnani (ed) Beta-adrenergic blocking agents in the management of hypertension and angina pectoris. Raven, New York, pp 117–137Google Scholar
  83. Brain MC, Caro RT, Kane J, Lyonnais J, Dollery CT (1974) Acute effects of varying doses of propranolol upon oxygen haemoglobin affinity in man. Br J Clin Pharmacol 1: 67–70Google Scholar
  84. Brann EG, Newman DJ (1973) Oxygen affinity in red cells: inability to show membranebound 2, 3-diphosphoglycerate. Science 179: 593Google Scholar
  85. Braunwald E (1971) Control of myocardial oxygen consumption. Physiological and clinical considerations. Am J Cardiol 27: 416–432PubMedGoogle Scholar
  86. Brecht HM, Banthien F, Schoeppe W (1976) Decrease in plasma noradrenaline levels following long-term treatment with pindolol in patients with essential hypertension. Klin Wochenschr 54: 1095–1105PubMedGoogle Scholar
  87. Breckenridge A (1982) Should every survivor of a heart attack be given a beta–blocker? Part II: Evidence from a clinical pharmacological stand point. Br Med J 285: 37–39Google Scholar
  88. Briant RH, Dollery CT, Fenyvesi T, George CF (1973) Assessment of selective beta-adrenoceptor blockade in man. Br J Pharmacol 49: 106–114PubMedGoogle Scholar
  89. Brisse B, Tetsch P, Jacobs W, Bender F (1982) B–adrenoceptor blockade in stress due to oral surgery. Br J Clin Pharmacol 13 [Suppl 2]: 421s–427sPubMedGoogle Scholar
  90. Brown EM, Fedak SA, Woodward CJ, Aurbach GD, Rodbard D (1976) Beta-adrenergic receptor interactions. Direct comparison of receptor interaction and biological activity. J Biol Chem 251: 1239–1246Google Scholar
  91. Brown P, Baddeley H, Read AE, Davis JD, McGarry J (1974) Sclerosing peritonitis, an unusual reaction to a ß-adrenergic blocking drug (practolol). Lancet 2: 1477–1481PubMedGoogle Scholar
  92. Bühler FR, Laragh JH, Baer L, Vaughan ED, Brunner HR (1972) Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin dependent hypertensive diseases. N Engl J Med 287: 1209–1214Google Scholar
  93. Cairns J A, Klassen GA (1981) Intravenous propranolol therapy for acute myocardial infarction in man. Chest 79: 277PubMedGoogle Scholar
  94. Campbell RWF, Murray A, Julian DG (1981) Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Br Heart J 46: 351–357PubMedGoogle Scholar
  95. Carmeliet E, Verdonck R (1967) Interaction between ouabain and butridine, a beta-adrenergic blocking substance on the heart. Eur J Pharmacol 1: 269–277Google Scholar
  96. Carruthers SG (1982) Cardiac dose-response relationships of oral and intravenous pindolol. Br J Clin Pharmacol 13: 193S–198SPubMedGoogle Scholar
  97. Castleden CM, George CF (1979) The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol 7: 49–54PubMedGoogle Scholar
  98. Challoner DR, Steinberg D (1966) Effect of free fatty acids on the oxygen consumption of perfused rat heart. Am J Physiol 210: 280–286PubMedGoogle Scholar
  99. Chamberlain DA (1966) Effects of ß-adrenergic blockade on heart size Am J Cardiol 18: 321–328Google Scholar
  100. Chamberlain DA, Green KG (1976) Morbidity and mortality in post-infarction patients under long-term treatment with a beta-adrenoceptor blocking agent. Postgrad Med J 52 [Suppl 4]: 153–154Google Scholar
  101. Chester EH, Shwartz HJ, Fleming GM (1981) Adverse effects of propranolol on airway function in non-astmatic chronic obstructive lung disease. Chest 79: 540–544PubMedGoogle Scholar
  102. Christensen NJ, Trap-Jensen J, Svendsen TL, Rasmussen S, Nielsen PE (1978) Effect of labetalol on plasma noradrenaline and adrenaline in hypertensive man. Eur J Clin Pharmacol 14: 227–230PubMedGoogle Scholar
  103. Clark BJ (1976) Pharmacology of beta-adrenoceptor blocking agents. In: Saxena PR, Forsyth RP (eds) Beta-adrenoceptor blocking agents. North-Holland, AmsterdamGoogle Scholar
  104. Clausen N, Damsgaard T, Mellemgaard K (1979) Antihypertensive effect of a non-selective (propranolol) and a cardioselective (metoprolol) ß-adrenoceptor blocking agent at rest and during exercise. Br J Clin Pharmacol 7: 379–383PubMedGoogle Scholar
  105. Cocco G, Sansano C, Hausmann M, Vallini R, Strozzi C, Chu D (1982) A review of the side effects of ß-adrenoceptor blocking drugs on the skin, mucosae and connective tissue. Curr Ther Res 31: 362–378Google Scholar
  106. Cody RJ, Calabrese LH, Clough JD, Tarazi RC, Bravo EL (1979) Development of antinuclear antibodies during acebutolol therapy. Clin Pharmacol Ther 25 (6): 800–805PubMedGoogle Scholar
  107. Cohn PF, Braunwald E (1980) Chronic coronary artery disease. In: Braunwald E (ed) Heart disease. A textbook of cardiovascular medicine. Saunders, Philadelphia, pp 1387–1436Google Scholar
  108. Coltart DJ (1971) Comparison of effects of propranolol and practolol on exercise tolerance in angina pectoris. Br Heart J 33: 62–64PubMedGoogle Scholar
  109. Coltart DJ, Gibson DG, Shand DG (1971) Plasma propranolol levels associated with suppression of ventricular ectopic beats. Br Med J 1: 490–491PubMedGoogle Scholar
  110. Crawford MH, LeWinter MM, O’Rourke RA, Karliner JS, Ross J (1975) Combined propranolol and digoxin therapy in angina pectoris. Ann Intern Med 83: 449–455PubMedGoogle Scholar
  111. Cruikshank JM (1980) The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J 100: 160–178Google Scholar
  112. Cruikshank JM (1981) Beta-blockers, bradycardia and adverse effects. Acta Ther 7: 309–319Google Scholar
  113. Cruikshank JM (1983) How safe are beta-blockers? Drugs 25 [Suppl 2]: 331–340Google Scholar
  114. Cumming AMM, Brown JJ, Fraser R, Lever AF, Morton JJ, Richards DA, Robertson JIS (1979) Blood pressure reduction by incremental infusion of labetalol in patients with severe hypertension. Br J Clin Pharmacol 8 (4): 359–364Google Scholar
  115. Dale HH (1906) On some physiological actions of ergot. J Physiol (London) 34: 163–206Google Scholar
  116. Daly K, Bergman G, Rothman M, Atkinson L, Jackson G, Jewitt DE (1982) Beneficial effect of adding nifedipine to beta-adrenergie blocking therapy in angina pectoris. Eur Heart J 3: 42–46PubMedGoogle Scholar
  117. Dargie HJ, Lynch PG, Krikler DM, Harris L, Krikler S (1981) Nifedipine and propranolol: a beneficial drug interaction. Am J Med 71: 676–682PubMedGoogle Scholar
  118. Davidson NMcD, Corrall RJM, Shaw TRD, French EB (1976) Observations in man of hypoglycaemia during selective and non-selective beta blockade. Scott Med J 22: 69–72Google Scholar
  119. Davies RO, Mizgala HF, Khan AS (1969) Propranolol-isosorbide dinitrate: combined therapy in angina pectoris. Clin Res 17: 635Google Scholar
  120. Day JL, Simpson N, Metcalfe J, Page RL (1979) Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J 1: 77–80PubMedGoogle Scholar
  121. Day JL, Metcalfe J, Simpson CN (1982) Adrenergic mechanisms in control of plasma lipid concentrations. Br Med J 284: 1145–1148Google Scholar
  122. Dayer P, Kubli A, Kupfer A, Courvoisier F, Ballant L, Fabre J (1982) Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. Br J Clin Pharmacol 13: 750–751PubMedGoogle Scholar
  123. Deacon SP (1978) The effects of atenolol and propranolol upon lipolysis. Br J Clin Pharmacol 5: 123–125PubMedGoogle Scholar
  124. Deacon SP, Karunayake A, Barnett D (1977) Acebutolol, atenolol and propranolol and metabolic responses to acute hypoglycaemia in diabetics. Br Med J 2: 1255–1257PubMedGoogle Scholar
  125. Decalmer PBS, Chattarjee SS, Cruickshank JM, Benson MK, Sterling GM (1978) Betablockers and asthma. Br Heart J 40: 184–189PubMedGoogle Scholar
  126. Deitchman D, LaBudde JA, Seidehamel RJ (1983) Bucindolol. In: Scriabine A (ed) New drugs annual: cardiovascular drugs. Raven, New York, pp 1–18Google Scholar
  127. Delage F, Rouleau JR, Labelle J-L, Dagenais G-R (1980) Effects of metoprolol on effort angina during the postprandial state. Clin Pharmacol Ther 27 (6): 763–768PubMedGoogle Scholar
  128. DelBianco PL, Bavazzano A, Frianchi G, Sicuteri F (1966) Pharmacological and therapeutic effects of adrenergic beta blockade. Boll Soc Ital Cardiol 11: 656–659Google Scholar
  129. Diaz RG, Somberg J, Freeman E, Levitt B (1974) Myocardial infarction after propranolol withdrawal. Am Heart J 88: 257–258PubMedGoogle Scholar
  130. DiBianco R, Singh SN, Shah PM, Carter Newton G, Miller RR, Nahormek P, Bortz Costello R, Laddu AR, Gottdiener JS, Fletcher RD (1982) Comparison of the antianginal efficacy of acebutolol and propranolol. A multicenter, randomized, double-blind placebo-controlled study. Circulation 65: 1119–1128Google Scholar
  131. Dintenfass L (1977) Viscosity factors in hypertensive and cardiovascular diseases. Cardiovasc Med 2: 337–354Google Scholar
  132. Distler A, Keim HJ, Cordes U, Philipp T, Wolff HP (1978) Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension. Am J Med 64: 446–451PubMedGoogle Scholar
  133. Dollery CT, Junod AF (1976) Concentration of (-h)-propranolol in isolated, perfused lungs of rat. Br J Pharmacol 57: 67–71PubMedGoogle Scholar
  134. Dominiak P, Grobecker H (1982) Elevated plasma catecholamines in young hypertensive and hyperkinetic patients: effect of pindolol. Br J Clin Pharmacol 13 [Suppl 2]: 381S–390SPubMedGoogle Scholar
  135. Drayer DE (1976) Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man and accumulation in renal failure. Clin Pharmacokinet 1: 426–443PubMedGoogle Scholar
  136. Drayer DE (1977) Active drug metabolites and renal failure. Am J Med 62: 486–489PubMedGoogle Scholar
  137. Duner H, Pernow B (1973) Haemodynamic effects of ß-receptor blocking agents and digitalis in ischaemic coronary heart disease with angina pectoris. Acta Med Scand 194: 517–523PubMedGoogle Scholar
  138. Durao V, Prata MM, Gongalves LM (1977) Modification of antihypertensive effect of beta-adrenoceptor blocking agents by inhibition of endogenous prostaglandin synthesis. Lancet 2: 1005–1007PubMedGoogle Scholar
  139. Dwyer EM, Pepe AJ, Pinkernell BH (1982) Effects of beta-adrenergic blockade with pindolol versus placebo in coronary patients with stable angina pectoris. Am Heart J 103 (5): 830–833PubMedGoogle Scholar
  140. Eastwood JB, Curtis JR, Smith RB (1973) Pharmacodynamics of practolol in chronic renal failure. Br Med J 4: 320–322PubMedGoogle Scholar
  141. Edwards RC, Raftery EB (1976) Haemodynamic effects of long-term oral labetalol. Br J Clin Pharmacol 3 [Suppl 3]: 733–736PubMedGoogle Scholar
  142. Ekberg G, Hansson B-G (1977) Glucose tolerance and insulin release in hypertensive patients treated with the cardioselective ß-receptor blocking agent metoprolol. Acta Med Scand 202: 393–397PubMedGoogle Scholar
  143. Eliasch H, Rosen A, Scott HM (1967) Systemic circulatory response to stress of simulated flight and to physical exercise before and after propranolol blockade. Br Heart J 29: 671–683PubMedGoogle Scholar
  144. Eliasson K, Lins L-E, Sundqvist K (1982) Peripheral vasospasm during ß-receptor blockade- a comparison between metoprolol and pindolol. Acta Med Scand [Suppl] 665: 109–112Google Scholar
  145. Ellis EF, Oelz O, Jackson Roberts L, Payne NA, Sweetman BJ, Nies AS, Oates J A (1976) Coronary arterial smooth muscle contraction by a substance released from platelets: Evidence that it is thromboxane A2. Science 193: 1135–1137PubMedGoogle Scholar
  146. Ellis ME, Sahay JN, Chattarjee SS, Cruickshank JM, Ellis SH (1981) Cardioselectivity of atenolol in asthmatic patients. Eur J Clin Pharmacol 21: 173–176PubMedGoogle Scholar
  147. Erikssen J, Thaulow E, Mundal R, Opstad P, Nitter-Hauge S (1982) Comparison of ß-adrenoceptor blockers under maximal exercise (pindolol v metoprolol v atenolol). Br J Clin Pharmacol 13: 201S–209SPubMedGoogle Scholar
  148. Esler M, Jackman G, Leonard P, Skews H, Bobik A, Jennings G (1981) Effect of propranolol on noradrenaline kinetics in patients with essential hypertension. Br J Clin Pharmacol 12: 375–380PubMedGoogle Scholar
  149. Falch DK, Odegaard AE, Norman N (1979) Decreased renal plasma flow during propranolol treatment in essential hypertension. Acta Med Scand 205: 91–95PubMedGoogle Scholar
  150. Felix RH, Ive FA, Dahl MGC (1974) Cutaneous and ocular reactions to practolol. Br Med J 4: 321–324PubMedGoogle Scholar
  151. Fitzgerald JD (1968) Effects of propranolol on blood sugar, insulin and free fatty acids. Diabetologia 5: 339Google Scholar
  152. Fitzgerald JD (1972) Beta adrenergic blocking drugs. Present position and future developments. Acta Cardiol [Suppl] 15: 199–216Google Scholar
  153. Fitzgerald JD (1976) The effect of ß-adrenoceptor antagonists on the morbidity and mortality in cardiovascular disease. Postgrad Med J 52: 770–781PubMedGoogle Scholar
  154. Fitzgerald JD, Ruffin R, Smedstad R, Roberts R, McAinsh J (1978) Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol 13: 81–89PubMedGoogle Scholar
  155. Fleckenstein A, Frey M, Fleckenstein-Grün G (1983) Consequences of uncontrolled calcium entry and its prevention with calcium antagonists. Eur Heart J 4 [Suppl H]: 43–50PubMedGoogle Scholar
  156. Folgering HThM, Borm JFE, van Haaren RHLM (1982) Metabolic aspects of maximal exercise performance after slow release metoprolol and after atenolol. Eur J Clin Pharmacol 23: 283–288PubMedGoogle Scholar
  157. Forrest WA (1972) A total of 254 cases of angina pectoris treated with oxprenolol in hospital practice - a monitored release study. Br J Clin Pract 26: 217–222PubMedGoogle Scholar
  158. Fox CA (1970) Reduction in the rise of systolic blood pressure during human coitus by the ß-adrenergic blocking agent, propranolol. J Reprod Fertil 22: 587–590PubMedGoogle Scholar
  159. Fox K, Jonathan A, Selwyn A (1980) Combined high-dosage administration of nifedipine and propranolol in patients with angina pectoris. Clin Sci 58: 11P–12 PGoogle Scholar
  160. Fox KM, Jonathan A, Selwyn AP (1981) The use of propranolol and nifedipine in the medical management of angina pectoris. Clin Cardiol 4: 125–129PubMedGoogle Scholar
  161. Fox KM, Deanfleld J, Krikler S, Ribeiro P, Wright C (1983) The influence of cigarette smoking on the medical management of angina. Drugs 25 [Suppl 2]: 177–180Google Scholar
  162. Frais MA, Bayley TJ (1979) Left ventricular failure with labetalol. Postgrad Med J 55: 567–568PubMedGoogle Scholar
  163. Franco-Morselli R, Baudouin-Legros M, Meyer P (1978) Plasma adrenaline and noradrenaline in essential hypertension and after long-term treatment with ß-adrenoceptor blocking agents. Clin Sci Mol Med 55 [Suppl 4]: 97s–100sGoogle Scholar
  164. Freestone S, Ramsay LE (1983) Effect of beta-blockade on the pressor response to coffee plus smoking in patients with mild hypertension. Drugs 25 [Suppl 2]: 141–145Google Scholar
  165. Frick MH, Luurila O (1976) Double-blind titrated-dose comparison of metoprolol and propranolol in the treatment of angina pectoris. Ann Clin Res 8: 385–392PubMedGoogle Scholar
  166. Frishman W (1979) Clinical pharmacology of the new beta-adrenergic blocking drugs, Part I. Pharmacodynamic and pharmacokinetic properties. Am Heart J 97: 663–670PubMedGoogle Scholar
  167. Frishman W (1980) Clinical pharmacology of the new beta-adrenergic blocking drugs, Part 9. Nadolol: A new long-acting beta-adrenoceptor. Am Heart J 99: 124–128PubMedGoogle Scholar
  168. Frishman W, Smithen C, Befler B, Kligfield P, Killip T (1975) Non-invasive assessment of clinical response to oral propranolol therapy. Am J Cardiol 35: 635–644PubMedGoogle Scholar
  169. Frishman WH, Christodoulou J, Weksler B, Smithen C, Killip T, Scheidt S (1978) Abrupt propranolol withdrawal in angina pectoris: effects on platelet aggregation and exercise tolerance. Am Heart J 95: 169–179PubMedGoogle Scholar
  170. Frishman WH, Kostis J, Strom J, Hossler M, Elkayam U, Goldner S, Silverman R, Davis R, Weinstein J, Sonnenblick E (1979) Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6. A comparison of pindolol and propranolol in the treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity. Am Heart J 98: 526–535Google Scholar
  171. Frishman WH, Klein NA, Strom JA, Willens H, LeJemtel TH, Jentzer J, Siegel L, Klein P, Kirschen N, Silverman R, Pollack S, Doyle R, Kirsten E, Sonnenblick EH (1982 a) Superiority of verapamil to propranolol in stable angina pectoris: a double-blind, randomized crossover trial. Circulation 65 (1) Part 11:1-51-1-59Google Scholar
  172. Frisk-Holmberg M, Jorfeldt L, Juhlin-Danfelt A (1977) Influence of long-term anti-hypertensive alprenolol treatment on hemodynamic and metabolic response to prolonged exercise in man. Clin Pharmacol Ther 21: 675PubMedGoogle Scholar
  173. Fulton RM, Green KG (1963) Effect of pronethalol in angina pectoris. Br Med J 2: 1228–1229Google Scholar
  174. Furburg B, Dahlqvist A, Raak A, Wrege U (1978) Comparison of the new beta-adrenoceptor antagonist, nadolol, and propranolol in the treatment of angina pectoris. Curr Med Res Opin 5: 388–393Google Scholar
  175. Furnival CM, Linden RJ, Snow HM (1970) Inotropic changes in the left ventricle: the effect of changes in heart rate, aortic pressure and end-diastolic pressure. J Physiol 211: 359PubMedGoogle Scholar
  176. George CF, Nagle RE, Pentecost BL (1970) Practolol in treatment of angina pectoris. A double-blind trial. Br Med J 2: 402–404Google Scholar
  177. Gianelly RS, Goldman RH, Treister B, Harrison DC (1967) Propranolol in patients with angina pectoris. Ann Intern Med 67: 1216–1225PubMedGoogle Scholar
  178. Gibelli A, Montanari C, Bellani D, Mandelli V, Sacchetti G (1973) Beta-blocking drugs and human platelet aggregation in vitro. Experimentia 29: 186–187Google Scholar
  179. Gibson DG (1974) Pharmacodynamic properties of ß-adrenergic blocking drugs in man. Drugs 7: 8–38PubMedGoogle Scholar
  180. Gibson DG (1977) Pharmacodynamic properties of ß-adrenoceptor blocking drugs in man. In: Avery GS (ed) ß-adrenoceptor blocking drugs; cardiovascular drugs, vol 2. Adis, Sydney, pp 1–40Google Scholar
  181. Gillam PMS, Prichard BNC (1965) Use of propranolol in angina pectoris. Br Med J 2: 337–339PubMedGoogle Scholar
  182. Gillam PMS, Prichard BNC (1966) Propranolol in the therapy of angina pectoris. Am J Cardiol 18: 366–369PubMedGoogle Scholar
  183. Ginn WM, Orgain ES (1966) Propranolol hydrochloride in the treatment of angina pectoris. JAMA 198: 1214–1216PubMedGoogle Scholar
  184. Gluck Z, Baumgartner G, Weidmann P, Pereim E, Bachmann C, Morsdasini R, Flammer J, Keusch G (1978) Increased ratio between serum B- and A-lipoproteins during diuretic therapy: an adverse effect? Clin Sci Mol Med 55: 325s–328sGoogle Scholar
  185. Godenir JP, Amor M, Cherrier F, Houppe JP, Karcher G, Bertrand A (1983) Atenolol in unstable angina. Clinical results and assessment of left ventricular function by radionuclide angiography. Drugs 25 [Suppl 2]: 172–176Google Scholar
  186. Gokal R, Dornan TL, Ledingham JGG (1979) Peripheral skin necrosis complicating betablockade. Br Med J 1: 721–722PubMedGoogle Scholar
  187. Goldreyer BN (1972) Intracardiac electrocardiography in the analysis and understanding of cardiac arrhythmias. Ann Intern Med 77: 117–136PubMedGoogle Scholar
  188. Goldstein RE, Corash LC, Tallman JF, Lake CR, Hyde J, Smith CC, Capurro NL, Anderson JC (1981) Shortened platelet survival time and enhanced heart rate responses after abrupt withdrawal of propranolol from normal subjects. Am J Cardiol 47: 1115–1122PubMedGoogle Scholar
  189. Gooding PG, Berman E (1974) An evaluation of sotalol, a ß-blocking agent, in patients with angina pectoris. Postgrad Med J 50: 734–736PubMedGoogle Scholar
  190. Graham BR, Littlejohns DW, Prichard BNC, Scales B, Southorn P (1973) Preliminary observations on the human pharmacology of I.C.1.66082 in normal volunteers. Br J Pharmacol 49: 154P–155 PPubMedGoogle Scholar
  191. Grandjean T, Rivier JL (1968) Cardio-circulatory effects of beta-adrenergic blockade in organic heart disease. Comparison between propranolol and CIBA 39,089-Ba. Br Heart J 30: 50–59PubMedGoogle Scholar
  192. Grandjean T, Hamer NJ, Sowton GE, Melendz L (1966) The effect of propranolol (“Inderal”) on effort tolerance in angina pectoris. Cardiologica 49 [Suppl 2]: 57–65Google Scholar
  193. Grant RHE, Keelan P, Kernohan RJ, Leonard JC, Nancekieville L, Sinclair K (1966) Multicenter trial of propranolol in angina pectoris. Am J Cardiol 18: 361–365PubMedGoogle Scholar
  194. Greefhorst APM, van Herwaarden CLA (1981) Comparative study of the ventilatory effects of three beta±-selective blocking agents in asthmatic patients. Eur J Clin Pharmacol 20: 417–421PubMedGoogle Scholar
  195. Greenblatt DJ, Koch-Weser J (1974) Adverse reactions to ß-adrenergic receptor blocking drugs. A report from the Boston Collaborative Drug Surveillance Program. Drugs 7: 118–129Google Scholar
  196. Greil W (1980) Central nervous system effects. Curr Ther Res 28: 106Google Scholar
  197. Gribbin HR, Baldwin CJ, Tattersfield AE (1979) Quantitative assessment of bronchial ß-adrenoceptor blockade in man. Br J Clin Pharmacol 7: 551–556PubMedGoogle Scholar
  198. Gribbin HR, Mackay AD, Baldwin CJ, Tattersfield AE (1981) Bronchial and cardiac ß-adrenoceptor blockade - a comparison of atenolol, acebutolol and labetalol. Br J Clin Pharmacol 12: 61–65PubMedGoogle Scholar
  199. Griffith DNW, James IM, Newbury PA, Woollard ML (1979) The effect of ß-adrenergic receptor blocking drugs on cerebral blood flow. Br J Clin Pharmacol 7: 491–494PubMedGoogle Scholar
  200. Gross F (1981) International experience with nadolol, a long-acting ß-blocking agent. In: Gross F (ed) Royal society of medicine international congress and symposium series No 37. Academic, LondonGoogle Scholar
  201. Gross GJ, Warltier DC, Hardman HF (1978) Beneficial actions of N-dimethyl propranolol on myocardial oxygen balance and transmural perfusion gradients distal to a severe coronary artery stenosis in the canine heart. Circulation 58: 663–669PubMedGoogle Scholar
  202. Guazzi M, Fiorentini C, Polese A, Olivari M, Magrini F (1976) Antihypertensive action of propranolol in man: lack of evidence for a neural depressive effect. Clin Pharmacol Ther 20: 304–309PubMedGoogle Scholar
  203. Gugler R, Bodem G (1978) Single and multiple dose pharmacokinetics of pindolol. Eur J Clin Pharmacol 13: 13–16PubMedGoogle Scholar
  204. Gugler R, Herold W, Dengler HJ (1974) Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol 7: 17–24PubMedGoogle Scholar
  205. Halkin H, Vered I, Saginer A, Rabinowitz B (1979) Once daily administration of sustained release propranolol capsules in the treatment of angina pectoris. Eur J Clin Pharmacol 16: 387–391PubMedGoogle Scholar
  206. Halprin S, Frishman W, Kirschner M, Strom J (1980) Clinical pharmacology of the new beta-adrenergic blocking drugs. Part II. Effects of oral labetalol in patients with both angina pectoris and hypertension: a preliminary experience. Am Heart J 99: 388–396PubMedGoogle Scholar
  207. Hampton JR (1981) The use of beta blockers for the reduction of mortality after myocardial infarction. Eur Heart J 2: 259–268PubMedGoogle Scholar
  208. Hampton JR (1982) Should every survivor of a heart attack be given a beta blocker? Part I: Evidence from clinical trials. Br Med J 285: 33–36Google Scholar
  209. Haneda T, Lee T, Ganz W (1973) Metabolic effects of propranolol in the ischaemic myocardium studied by regional sampling. Circulation 48 [Suppl 4]: 174Google Scholar
  210. Hansen PF, Rasmussen PA, Nyberg G (1973) Alprenalol alone and in conjunction with pentanitrol in angina pectoris. Acta Med Scand 193: 419–424PubMedGoogle Scholar
  211. Hansson BG, Hokfelt B (1975) Prolonged treatment with penbutolol (HOE 893d) in patients with moderated hypertension I. Effects on blood pressure and pulse rate, catecholamines in blood and urine, plasma renin activity and urinary aldosterone under basal conditions and following exercise. Eur J Clin Pharmacol 9: 9–19Google Scholar
  212. Hansson BG, Dymling JF, Hedeland H, Hulthen UL (1977) Long-term treatment of moderated hypertension with the beta-receptor blocking agent metoprolol. Eur J Clin Pharmacol 11: 239–245PubMedGoogle Scholar
  213. Hansson L (1973) Beta-adrenergic blockade in essential hypertension. Effects of propranolol on haemodynamic parameters and plasma renin activity. Acta Med Scand 55 [Suppl 1]: 1–40Google Scholar
  214. Hansteen V, Minichen E, Lorensten E, Anderson A, Strom O, Soiland K, Dyrbekk D, Refsun A-M, Tromsdal A, Knudsen K, Eika C, Bakken J, Smith P, Hoff PI (1982) One year’s treatment with propranolol after myocardial infarction; preliminary report of Norwegian multicentre trial. Br Med J 284: 155–160Google Scholar
  215. Hares P, James IM, Griffith D (1977) The effect of acebutolol on the cerebral circulation of man. Br J Clin Pharmacol 4: 373–375PubMedGoogle Scholar
  216. Harley BJS, Davies RO (1968) Propranolol in the office treatment of angina pectoris. Can Med Assoc J 99: 527–530PubMedGoogle Scholar
  217. Hartling OJ, Noer I, Svendsen TL, Clausen JP, Trap-Jensen J (1980) Selective and nonselective ß-adrenoceptor blockade in the human forearm. Clin Sci 58: 279–286PubMedGoogle Scholar
  218. Heatherington DJ, Comerford MB, Nyberg G, Besterman EMM (1973) Comparison of two adrenergic beta-blocking agents, alprenolol and propranolol, in the treatment of angina pectoris. Br Heart J 35: 320–333Google Scholar
  219. Hebb AR, Goodwin TF, Gunton RW (1968) A new beta-adrenergic blocking agent, propranolol in the treatment of angina pectoris. Can Med Assoc J 98: 246–251PubMedGoogle Scholar
  220. Heck I, Trübestein G, Stumpe KO (1981) Effects of combined alpha- and beta-receptor blockade on peripheral circulation in essential hypertension. Clin Sci 61: 429S–432SPubMedGoogle Scholar
  221. Heel RC, Brodgen GE, Speight TM, Avery GS (1980) Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 20: 1–23PubMedGoogle Scholar
  222. Heel RC, Brogden RN, Speight TM, Avery GS (1981) Penbutolol: a preliminary review of its pharmacological efficacy in hypertension and angina pectoris. Drugs 22: 1–25PubMedGoogle Scholar
  223. Heikkila J, Nieminen MS (1978) Rapid monitoring of regional myocardial ischaemia with echocardiography and ST segment shifts in man. Acta Med Scand [Suppl] 623: 71–95Google Scholar
  224. Hesse B, Pedersen JT (1973) Hypoglycaemia after propranolol in children. Acta Med Scand 193: 551–552PubMedGoogle Scholar
  225. Hickie JB (1970) Alprenolol (Aptin) in angina pectoris. A double-blind multicentre trial. Med JAust 2: 268–272Google Scholar
  226. Hillis WS, Tweddel AC, Murray RG, Lawrie TDV (1980) Comparative study of the effects of penbutolol and propranolol in the treatment of angina pectoris. Arzneimittelforsch 30: 1595–1599PubMedGoogle Scholar
  227. Himms-Hagen J (1972) Effects of catecholamines on metabolism. In: Blaschko H, Muscholl E (eds) Catecholamines. Springer, Berlin Heidelberg New York, pp 363–441 (Handbook of experimental pharmacology, vol 33 )Google Scholar
  228. Hitzenberger G, Fitscha P, Beveridge T, Nuesch E, Pacha W (1982) Effects of age and smoking on the pharmacokinetics of pindolol and propranolol. Br J Clin Pharmacol 13: 217S–222SPubMedGoogle Scholar
  229. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wilhelmsson C (1981) Effect on mortality of metoprolol in acute myocardial infarction. Lancet 2: 823–827PubMedGoogle Scholar
  230. Hoffman BF, Singer DH (1967) Appraisal of the effects of catecholamines on cardiac electrical activity. Ann NY Acad Sci 139: 914–939PubMedGoogle Scholar
  231. Hoffman K-J, Regardh C-G, Aurell M, Ervik H, Jordo L (1980) The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites. Clin Pharmacokinet 5: 181–191Google Scholar
  232. Hollenberg NK, Adams DF, McKinstry D, Williams GN, Borucki LJ, Sullivan J (1979) Beta-adrenoceptor blocking agents and the kidney: effect of nadolol and propranolol on the renal circulation. Br J Clin Pharmacol 7 [Suppl 2]: 219–226Google Scholar
  233. Hombach V, Hopp H-W, Braun V, Gil-Sanchez D, Deutsch H, Behrenbeck DW, Tauchert M, Hilger HH (1983) Relevance of physical activity to the antianginal effects of betablockade on supraventricular tachycardia. Drugs 25 [Suppl 2]: 186–192Google Scholar
  234. Horn ME, Prichard BNC (1973) A variable dose comparative trial of propranolol and sotalol in angina pectoris. Br Heart J 35: 555PubMedGoogle Scholar
  235. Houben H, Thien TH, Van’T Laar A (1981) Haemodynamic effects of cigarette smoking during chronic selective and non-selective beta-adrenoceptor blockade in patients with hypertension. Br J Clin Pharmacol 12: 67–72PubMedGoogle Scholar
  236. Hultgren HN, Pfeiffer JF, Angel WW, Bilisoly J (1977) Unstable angina: comparison of medical and surgical management. Am J Cardiol 39: 734–740PubMedGoogle Scholar
  237. Ibrahim MM, Madkour MA, Moussallam R (1980) Effect of atenolol on left ventricular function in hypertensive patients. Circulation 62 (5): 1036–1046PubMedGoogle Scholar
  238. Ingram DM, House AK, Thompson GH, Stacey MC, Castleden WM, Lovegrove FT (1982) Beta-adrenergic blockade and peripheral vascular disease. Med J Aust 1 (12): 509–511PubMedGoogle Scholar
  239. Ingram GIC, Jones RV (1966) The rise in clotting Factor VIII induced in man by adrenaline: effect of alpha and beta-blockers. J Physiol 187: 447–454PubMedGoogle Scholar
  240. Ireland MA, Littler WA (1981) The effects of oral acebutolol and propranolol on forearm blood flow in hypertensive patients. Br J Clin Pharmacol 12: 363–368PubMedGoogle Scholar
  241. Irving MH, Britton BJ. Wood WG, Padgham C, Carruthers M (1974) Effects of beta-adrenergic blockade on plasma catecholamines in exercise. Nature 248: 531–533PubMedGoogle Scholar
  242. Ishizaki T, Hirayama H, Tawara K, Nakaya H, Sato M, Sato K (1980) Pharmacokinetics and pharmacodynamics in young normal and elderly hypertensive subjects: a study using sotalol as a model drug. J Pharm Exp Ther 212: 173–181Google Scholar
  243. Jachuck SJ, Bird T, Stephenson J, Jackson ES, Clark F (1977) Practolol-induced autoantibodies and their relation to oculo-cutaneous complications. Postgrad Med J 53 (616): 75–77PubMedGoogle Scholar
  244. Jack DB, Kendall MJ, Wilkins M, Quarterman CP (1983) Oxidation phenotype and betablockers. N Engl J Med 308 (16): 964Google Scholar
  245. Jackson G, Atkinson L, Oram S (1975) Reassessment of failed beta-blocker treatment in angina pectoris by peak-exercise heart rate measurements. Br Med J 3: 616–618PubMedGoogle Scholar
  246. Jackson G, Harry JD, Robinson C, Kitson D, Jewitt DE (1978) Comparison of atenolol with propranolol in the treatment of angina pectoris with special reference to once daily administration of atenolol. Br Heart J 40: 998–1004PubMedGoogle Scholar
  247. Jaillon P, Weissenburger J, Biour M, Cheymol G, Haegle K, Schecter P, Koch-Weser J (1982) P- and α-adrenoceptor antagonism by medroxolol in healthy volunteers: relationship to dose and plasma concentration. J Cardiovasc Pharm 4: 705–713Google Scholar
  248. Jenkins RM, Nagle RE (1982) The symptomatic and objective effects of nifedipine in combination with beta-blocker therapy in severe angina pectoris. Postgrad Med J 58: 697–700PubMedGoogle Scholar
  249. Johnson SM, Mauritson DR, Corbett JR, Woodward W, Willerson JT, Hillis LD (1981) Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am J Med 71: 443–451PubMedGoogle Scholar
  250. Johnsson G (1975) Influence of metoprolol and propranolol on haemodynamic effects induced by adrenaline and physical work. Acta Pharmacol Toxicol 36 [Suppl 5]: 59–68Google Scholar
  251. Johnsson G, Regardh C-G (1976) Clinical pharmacokinetics of beta-adrenoceptor blocking drugs. Clin Pharmacokinet 1: 233–263PubMedGoogle Scholar
  252. Jones DH, Daniel J, Hamilton CA, Reid JL (1980) Plasma noradrenaline concentration in essential hypertension during long-term beta-adrenoceptor blockade with oxprenolol. Br J Clin Pharmacol 9: 27–31PubMedGoogle Scholar
  253. Jorgensen CR, Wang K, Wang Y, Gobel FL, Nelson RR, Taylor HL (1973) Effect of propranolol on myocardial oxygen consumption and its haemodynamic correlates during upright exercise. Circulation 48: 1173–1182PubMedGoogle Scholar
  254. Juhlin-Dannfelt A (1982) Metabolic effects of beta-adrenoceptor blockade on skeletal muscle at rest and during exercise. Acta Med Scand [Suppl] 665: 113–115Google Scholar
  255. Juhlin-Dannfelt A, Astrom H, (1979) Influence of beta-adrenoceptor blockade on leg blood flow and lactate release in man. Scand J Clin Lab Invest 39: 179PubMedGoogle Scholar
  256. Julian DG, Jackson FS, Prescott RJ, Szekely P (1982) Controlled trial of sotalol for one year after myocardial infarction. Lancet 1: 1142–1147PubMedGoogle Scholar
  257. Kadish A, Oka Y, Becker R, Frater R, Lin YT, Frishman W (1979) Propranolol withdrawal: cause of post-coronary bypass arrhythmias and hypertension. Circulation 60: 104Google Scholar
  258. Kaijser L, Kaiser P, Karlsson J, Rossner S (1980) Beta-blockers and running. Am Heart J 100 (6 pt I): 943–944PubMedGoogle Scholar
  259. Kaltenbach M, Guldner N (1972) Zur Behandlung der Koronarinsuffizienz mit B-Sympathikolytika. In: Dengler HJ (ed) Die therapeutische Anwendung B-sympathikolytischer Stoffe. Schattauer, Stuttgart, pp 123–141Google Scholar
  260. Keber I, Jerse M, Keber D, Stegnar M (1979) The influence of combined treatment with propranolol and acetylsalicylic acid on platelet aggregation in coronary heart disease. Br J Clin Pharmacol 7: 287–291PubMedGoogle Scholar
  261. Keelan P (1965) Double-blind trial of propranolol (Inderal) in angina pectoris. Br Med J 1: 897–898PubMedGoogle Scholar
  262. Kelly JG, McGarry K, O’Malley K, O’Brien ET (1982) Bioavailability of labetalol increases with age. Br J Clin Pharmacol 14: 304–305PubMedGoogle Scholar
  263. Kendall MJ, Quarterman CP, Bishop H, Schneider RE (1979) Effects of inflammatory disease on plasma oxprenolol concentrations. Br Med J 2: 465–468PubMedGoogle Scholar
  264. Keyrilainen O, Nyberg G, Uusitalo AJ (1973) Effects of alprenolol and isosorbide dinitrate in angina pectoris. Acta Med Scand 193: 281–292PubMedGoogle Scholar
  265. Khambatta RB (1974) Comparison of a new beta-receptor blocking agent acebutolol (Sectral) and propranolol. Clin Trials J 11 [Suppl 3]: 59–67Google Scholar
  266. Kirsten R, Beintz B, Bohmer D, Nelson K, Roth S, Welzel D (1982) Relationship of plasma catecholamines to blood pressure in hypertensive patients during beta-adrenoceptor blockade with and without intrinsic sympathomimetic activity. Br J Clin Pharmacol 13 [Suppl 2]: 397S–406SPubMedGoogle Scholar
  267. Kjekshus KJ, Mjos OD (1973) Effect of inhibition of lipolysis on infarct size after experimental coronary artery occlusion. J Clin Invest 52: 1770–1778PubMedGoogle Scholar
  268. Kligfeld P, Horner H, Smithen C, Brachenfeld N (1975) Metabolic effect of propranolol on ischaemic myocardium. Circulation 51 [Suppl 2]: 26Google Scholar
  269. Kloner RA, Reimer KA, Jennings RB (1976) Distribution of coronary collateral flow in acute myocardial ischaemic injury: effect of propranolol. Cardiovasc Res 10: 81–90PubMedGoogle Scholar
  270. Kloner RA, Fishbein MC, Cotran RS, Braunwald E, Maroko PR (1977) The effect of propranolol on microvascular injury in acute myocardial ischaemia. Circulation 55: 872–880PubMedGoogle Scholar
  271. Koch G (1976) Combined alpha- and beta-adrenoceptor blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise. Br J Clin Pharmacol 3 [Suppl 3]: 729–732PubMedGoogle Scholar
  272. Koch G, Franz IW, Lohmann FW (1981) Effects of short-term and long-term treatment with cardioselective and non-selective beta receptor blockade on carbohydrate and lipid metabolism and on plasma catecholamines at rest and during exercise. Clin Sci 61 [Suppl 7]: 433s–435sPubMedGoogle Scholar
  273. Kolendorf K, Bonnevie-Neilson V, Broch-Moller B (1982) A trial of metoprolol in hypertensive insulin dependent diabetic patients. Acta Med Scand 211 (3): 175–178PubMedGoogle Scholar
  274. Kostis JB, Frishman W, Krieger S, Cosgrove N, Hosier M, Kuo PT (1982 b) Once-a-day administration of pindolol in angina. Clin Pharmacol Ther 31(2):240 (Abstr) B5 240Google Scholar
  275. Krauss XH, Schalekamp MADH, Kolsters G, Zaal GA, Birkenhager WH (1972) Effects of chronic beta-adrenergic blockade on systemic and renal haemodynamic responses to hyperosmotic saline in hypertensive patients. Clin Sci 43: 385–391PubMedGoogle Scholar
  276. Krikler DM, Spurrell RAJ (1974) Verapamil in the treatment of paroxysmal supraventricular tachycardia. Postgrad Med J 50: 447–453PubMedGoogle Scholar
  277. Kristensen BO, Steiness E, Weeke J (1978) Propranolol withdrawal and thyroid hormones in patients with essential hypertension. Clin Pharmacol Ther 23: 624–629PubMedGoogle Scholar
  278. Kumana CR, Marlin GE, Kaye CM, Smith DM (1974) New approach to assessment of cardioselectivity of beta-blocking drugs. Br Med J 4 (5942): 444–447PubMedGoogle Scholar
  279. Kurien VA, Oliver MF (1966) Serum free fatty acids after acute myocardial infarction and cerebral vascular occlusion. Lancet 2: 122–127PubMedGoogle Scholar
  280. Kurien VA, Yates PA, Oliver MF (1969) Free fatty acids, heparin, and arrhythmias during experimental myocardial infarction. Lancet 2: 185–187PubMedGoogle Scholar
  281. Lambert D (1976) Effect of propranolol on mortality in patients with angina. Postgrad Med J 52 [Suppl 4]: 57–60PubMedGoogle Scholar
  282. Lammintausta R, Syvalahti E, Iisalo E, Kanto J, Mantyla R (1977) Selective and non-selective beta-blockade in renin release. Acta Pharmacol Toxicol (Copenh) 41: 489–496Google Scholar
  283. Lands AM, Arnold A, McAuliff FP, Luduena FP, Brown TG (1967) Differentiation of receptor systems activated by sympathomometic amines. Nature 214: 597–598PubMedGoogle Scholar
  284. Langley JN (1905) On the reactions on cells and of nerve endings to certain poisons, chiefly as regards the reaction of striated muscles to nicotine and to curare. J Physiol 33: 374–413PubMedGoogle Scholar
  285. Larsson K (1982) Influence of labetalol, propranolol and practolol in patients with asthma. Eur J Resp Dis 63: 221–230Google Scholar
  286. Lee RJ, Evans DB, Baky SH, Laffan RJ (1975) Pharmacology of nadolol (SQ 11725) a beta-adrenergic antagonist lacking direct myocardial depression. Eur J Pharmacol 33: 371–382PubMedGoogle Scholar
  287. Leenen FHH (1979) Possible significance of the pharmacological differentiation of betablockers for therapy of hypertension. Br J Clin Pharmacol 7 [Suppl 2]: 173S–184SPubMedGoogle Scholar
  288. Leenen FHH, van der Vijgh AB (1981) Regular propranolol versus slow-release propranolol in angina pectoris. Curr Ther Res 30 (1): 113–121Google Scholar
  289. Leenen FHH, Coenen CHM, Zonderland M, Maas AH (1980) Effects of cardioselective and non-selective beta-blockade on dynamic exercise performance in mildly hypertensive men. Clin Pharmacol Ther 28: 12–21PubMedGoogle Scholar
  290. Lees GM (1981) A hithchiker’s guide to the galaxy of adrenoceptors. Br Med J 283 (6285): 173 - 8Google Scholar
  291. Lefkowitz RJ (1976) B-adrenergic receptors: recognition and regulation. N Engl J Med 295: 323–328PubMedGoogle Scholar
  292. Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Niskanen J (1982) Effect of pindolol on serum lipids and lipid metabolizing enzymes. Br J Clin Pharmacol 13 [Suppl 2]: 445S–447SPubMedGoogle Scholar
  293. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF (1982) Oxidation phenotype - a major determinant of metoprolol metabolism and response. N Engl J Med 307: 1558–1560PubMedGoogle Scholar
  294. Lennard MS, Freestone S, Ramsay LE, Tucker GT, Woods HF (1983) Oxydation phenotype and beta-blockers. N Engl J Med 308 (16): 965Google Scholar
  295. Lichtman MA, Cohen J, Murphy NS, Kearney EA, Whitbeck AA (1974) Effect of propranolol on oxygen binding to haemaglobin in vitro and in vivo. Circulation 49: 881–886PubMedGoogle Scholar
  296. Lijnen PJ, Amery AK, Fagard RH, Reybrouck TM, Moerman EJ, De Schaepdryver AF (1979) The effects of beta-adrenoceptor blockade on renin, angiotensin, aldosterone and catecholamines at rest and during exercise. Br J Clin Pharmacol 7: 175–181PubMedGoogle Scholar
  297. Livesley B, Catley PF, Campbell RC, Oram S (1973) Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. Br Med J 1: 375–378PubMedGoogle Scholar
  298. Lombardo TA, Rose LR, Taeschler M, Tuluy S, Bing RJ (1953) The effect of exercise on coronary blood flow, myocardial oxygen consumption and cardiac efficiency in man. Circulation 7: 71–78PubMedGoogle Scholar
  299. Lopez-Ovejero J A, Weber MA, Drayer JIM, Sealey JE, Laragh JH (1978) Effects of indomethacin alone and during diuretic or beta-adrenoceptor-blockade therapy on blood pressure and the renin system in essential hypertension. Clin Sci Mol Med 55: 203S–205SGoogle Scholar
  300. Lowenthal DT, Briggs WA, Gibson TP, Nelson H, Cirksena WJ (1974) Pharmacokinetics of oral propranolol in chronic renal disease. Clin Pharmacol Ther 16: 761–769PubMedGoogle Scholar
  301. Lown B, Wolf M (1971) Approaches to sudden death from coronary heart disease. Circulation 44: 130–142PubMedGoogle Scholar
  302. Ludbrook P, Karliner JS, Kostuk W, O’Rourke RA (1973) Effects of intravenously administered propranolol on wall motion abnormalities. Am J Cardiol 31: 712–717PubMedGoogle Scholar
  303. Lund-Johansen P (1976 a) Hemodynamic long-term effects of timolol at rest and during exercise in essential hypertension. Acta Med Scand 199:263–267Google Scholar
  304. Lund-Johansen P (1976 b) Haemodynamic long-term effects of a new ß-adrenoceptor blocking drug atenolol (I.C.I. 66082) in essential hypertension. Br J Clin Pharmacol 3:445–451Google Scholar
  305. Lund-Johansen P (1979) Comparative haemodynamic effects of labetalol, timolol, prazosin and the combination of tolamolol and prazosin. Br J Clin Pharmacol 8 [Suppl 2]:107s-1 lisGoogle Scholar
  306. Lund-Larsen PG, Sivertssen E (1969) Haemodynamic effects of propranolol (Inderal) and H 56/28 (Aptin) in patients with acute myocardial infarction. A comparative study. Acta Med Scand 186: 187–191Google Scholar
  307. Lynch P, Dargie H, Krikler S, Krikler D (1980) Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine and their combination. Br Med J 281: 184–187PubMedGoogle Scholar
  308. Lyon LJ, Nevins MA (1971) Alprenolol treatment of angina pectoris. JAMA 215: 1669PubMedGoogle Scholar
  309. MacAlpin RN, Kattus AA, Winfield ME (1965) The effect of a ß-adrenergic blocking agent ( Nethalide) and nitroglycerin on exercise tolerance in angina pectoris. Circulation 31: 869–875Google Scholar
  310. Mackie IA, Seal DV, Pescod JM (1977) Beta-adrenergic receptor blocking drugs: tear lysozyme and immunological screening for adverse reaction. Br J Ophthalmol 61: 354–359PubMedGoogle Scholar
  311. Maconochie JG, Richards DA, Woodings EP (1977) Modification of pressor responses induced by “cold”. Br J Clin Pharmacol 4: 389 PGoogle Scholar
  312. Magnani B, Mantovani B, Brancaleoni M, Gubelli S, Ambrosioni E (1983) Cardioselectivity and partial agonist activity in the angianginal efficacy of the ß-adrenoceptor antagonists. A clinical comparison between atenolol and pindolol. Drugs 25 [Suppl 2]: 166–171Google Scholar
  313. Majid PA, van der Vijgh WJF, de Feijter PJ, Wardeh R, van der Wall EE, Roos JP (1979) Once daily atenolol (Tenormin) in the treatment of angina pectoris. Observations on clinical efficacy, pharmacokinetics and pharmacodynamics. Eur J Cardiol 9: 419–435Google Scholar
  314. Maling TJB, Dollery CT (1979) Changes in blood pressure, heart rate and plasma noradrenaline concentration after sudden withdrawal of propranolol. Br Med J 2: 366–367PubMedGoogle Scholar
  315. Manalan AS, Besch HR Jr, Watanabe AM (1981) Characterization of [3H] (+/-) carazolol binding to beta-adrenergic receptors. Application to study of beta-adrenergic receptor subtypes in canine ventricular myocardium and lung. Circulation Res 49 (2): 326–336PubMedGoogle Scholar
  316. Man in’t Veld AJ, Schalekamp MADH (1982) How intrinsic sympathomimetic activity modulates the haemodynamic responses to b-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism. Br J Clin Pharmacol 13 [Suppl 2]: 245S–257SGoogle Scholar
  317. Manninen V (1970) Movements of sodium and potassium and their traces in propranololtreated red cells and diaphragm muscles. Acta Physiol Scand 335 [Suppl]: 1–76Google Scholar
  318. Marigold JH, Pounder RE, Pemberton J, Thompson RPH (1982) Propranolol, oxprenolol and sclerosing peritonitis. Br Med J 284: 870Google Scholar
  319. Maroko PR, Braunwald E (1973) Modification of myocardial infarction size after coronary occlusion. Ann Intern Med 79: 720–733PubMedGoogle Scholar
  320. Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J, Braunwald E (1971) Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43: 67–82PubMedGoogle Scholar
  321. Maroko PR, Libby P, Braunwald E (1972) Effects of pharmacologic interventions on left ventricular function in the severely ischaemic heart. Circulation 46 [Suppl 2]: 29Google Scholar
  322. Marshall AJ, Roberts CJC, Barritt DW (1976) Raynaud’s phenomenon as side effect of beta-blockers in hypertension. Br Med J 1: 1498–1499PubMedGoogle Scholar
  323. Marx PG, Reid DS (1979) Labetalol infusion in acute myocardial infarction with systemic hypertension. Br J Clin Pharmacol 8 [Suppl 2]: 233s–238sPubMedGoogle Scholar
  324. McDevitt DG (1977) The assessment of ß-adrenoceptor blocking drugs in man. Br J Clin Pharmacol 4: 413–425PubMedGoogle Scholar
  325. McDevitt DG (1978) Beta-adrenoceptor antagonists and respiratory function. Br J Clin Pharmacol 5: 97–99PubMedGoogle Scholar
  326. McDevitt DG, Frisk-Holmberg M, Hollifield JW, Shand DG (1976) Plasma binding and the affinitiy of propranolol for a beta receptor in man. Clin Pharmacol Ther 20: 152–157PubMedGoogle Scholar
  327. McDevitt DG, Colin Brown H, Carruthers SG, Shanks RG (1977) Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther 21: 556–566PubMedGoogle Scholar
  328. McGibney D, Singleton W, Silke B, Taylor SH (1983) Observations on the mechanism underlying the differences in exercise and isoprenaline tachycardia after cardioselective and nonselective b-adrenoceptor antagonists. Br J Clin Pharmacol 15: 15–19PubMedGoogle Scholar
  329. McGonigle RJS, Williams L, Murphy MJ, Parsons V (1981) Labetalol and lipids. Lancet 1 (8212): 163PubMedGoogle Scholar
  330. Mehta J, Mehta P, Pepine CJ (1978) Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease. 3. Role of tachycardia stress and propranolol. Circulation 58 [No 5]: 881–886PubMedGoogle Scholar
  331. Meier A, Schiffl H, Weidmann P, Mordasini R, Riesen W, Bachmann C (1981) Beta-receptor-blocking agents may reverse or prevent diuretic-induced increases in serum lowdensity lipoprotein in cholesterol. Clin Sci 61: 437s–439sPubMedGoogle Scholar
  332. Meinertz T, Hajorg, Kasfer W, Kersting F, Heinz-Brluing K (1979) Beta-blocker withdrawal syndrome? Lancet 1: 270PubMedGoogle Scholar
  333. Melander A, Danielson K, Schersten B, Wahlin E (1977) Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther 22: 108–112PubMedGoogle Scholar
  334. Mehta J, Cohn JN (1977) Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation 55: 370–375PubMedGoogle Scholar
  335. Michelakis AM, McAllister RG (1972) The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J Clin Endocrinol metab 34: 386–394PubMedGoogle Scholar
  336. Miettinen TA, Vanhanen H, Huttunen JK, Vanhanen H, Huttunen JK, Naukkarinen V, Mattila S, Standberg T, Kumlin T (1982) HDL cholesterol and beta-adrenoceptor blocking agents in a five year multifactorial primary prevention trial. Br J Clin Pharmacol 13 [Suppl 2]: 431S–434SPubMedGoogle Scholar
  337. Miller RR, Olson HG, Amsterdam EA, Mason DT ( 1975 a) Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med 293: 416–418Google Scholar
  338. Miller RR, Olson HG, Pratt CM, Amsterdam EA, Mason DT ( 1975 b) Efficacy of betaadrenergic blockade in coronary heart disease: Propranolol in angina pectoris. Clin Pharmacol Ther 18: 598–605Google Scholar
  339. Mitchinson MJ (1972) Some clinical aspects of idiopathic retroperitoneal fibrosis. Br J Surg 59: 58–60PubMedGoogle Scholar
  340. Mizgala HF, Counsell J (1976) Acute coronary syndromes following abrupt cessation of oral propranolol therapy. Can Med Assoc J 114, No. 12: 1123–1126PubMedGoogle Scholar
  341. Mizgala HG, Khan AK, Davies RO (1969) Propranolol in the prophylactic treatment of angina pectoris. Can Med Assoc J 100: 756–764PubMedGoogle Scholar
  342. Mjos OD (1971) Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest 50: 1386–1389PubMedGoogle Scholar
  343. Mjos OD, Kjekshus JK, Lekven J (1974) Importance of free fatty acids as a determinant of myocardial oxygen consumption and myocardial ischaemic injury during norepinephrine infusion in dogs. J Clin Invest 53: 1290–1299PubMedGoogle Scholar
  344. Moir TW (1972) Subendocardial distribution of coronary blood flow and the effect of antianginal drugs. Circ Res 30: 621–627PubMedGoogle Scholar
  345. Molinoff PB, Aarons RD, Nies AS, Gerber JG, Wolfe BB, Goens MB (1982) Effects of pindolol and propranolol on ß-adrenergic receptors on human lymphocytes. Br J Clin Pharmacol 13 [Suppl 2]: 365sPubMedGoogle Scholar
  346. Moran NC, Perkins ME (1958) Adrenergic blockade of the mammalian heart by a dichloro-analogue of isoproterenol. J Pharmacol Exp Ther 124: 223–237PubMedGoogle Scholar
  347. Morganti A, Pickering TG, Lopez-Ovejero JA, Laragh JH (1979) Contrasting effects of acute beta blockade with propranolol on plasma catecholamines and renin in essential hypertension: a possible basis for the delayed antihypertensive response. Am Heart J 98: 490–494PubMedGoogle Scholar
  348. Morrison SC, Kumana CR, Rudnick KV, Haynes B, Jones NL (1982) Selective and nonselective beta-adrenoceptor blockade in hypertension: responses to changes in posture, cold and exercise. Circulation 65 (6): 1171–1177PubMedGoogle Scholar
  349. Moses JW, Wertheimer JH, Bodenheimer MM, Banka VS, Feldman M, Helfant RH (1981) Efficacy of nifedipine in rest angina refractory to propranolol and nitrates in patients with obstructive coronary artery disease. Ann Intern Med 94: 425–429PubMedGoogle Scholar
  350. M.R.C. Report (1981) Report of Medical Research Council Working Party on mild to moderate hypertension: adverse reactions to bendrofluozide and propranolol for the treatment of mild hypertension. Lancet 2: 539–543Google Scholar
  351. Mueller HS, Ayres S (1976) The “diabetic-like” response of the heart in acute myocardial infarction. Circulation 54 [Suppl 2]: 132Google Scholar
  352. Mueller HS, Ayers SM, Religa A, Evans RG (1974) Propranolol in the treatment of acute myocardial infarction. Effect on myocardial oxygen and hemodynamics. Circulation 49: 1078–1087Google Scholar
  353. Muiesan G, Porcellati C, Renzini V, Brunori CA, Valori C, Gigli G (1970) Relationship between plasma catecholamines and free fatty acid concentrations in patients with acute myocardial infarction. Cardiovasc Res 4: 226Google Scholar
  354. Muiesan G, Alicandri C, Rosei AE, Motolese M, Valori C (1975) Effect of oxprenolol on catecholamines and plasma renin activity: acute response to frusemide in hypertensive patients. Clin Sci Mol Med 48: 85s–88sGoogle Scholar
  355. Multicentre International Study (1975) Improvement in prognosis of myocardial infarction by long-term beta-adrenoceptor blockade using practolol. Br Med J 3: 735–740Google Scholar
  356. Myers MG, Wisenberg G (1977) Sudden withdrawal of propranolol in patients with angina pectoris. Chest 71: 24–26PubMedGoogle Scholar
  357. Myers MG, Freeman MR, Juma ZA, Wisenberg G (1979) Propranolol withdrawal in angina pectoris. A prospective study. Am Heart J 97: 298–302Google Scholar
  358. Nair DV (1972) A double-blind trial of Visken, LB 46, in the treatment of angina pectoris. Indian Heart J 3 [Suppl 1]: 183–191Google Scholar
  359. Nathan AW, Hellestrand KJ, Bexton RS, Ward DE, Spurrell RA, Camm AJ (1982) Electrophysiological effects of sotalol - just another beta blocker? Br Heart J 47 (6): 515–520PubMedGoogle Scholar
  360. Nattel S, Rangno RE, van Loon G (1979) Mechanism of propranolol withdrawal phenomena. Circulation 59: 1158–1164PubMedGoogle Scholar
  361. Nayler WG (1981) Beta blockers in experimental myocardial infarction. Acta Med Scand [Suppl] 651: 139–145Google Scholar
  362. Nayler WG, Mclnnes I, Swann JB, Carson V, Lowe TE (1967) Effect of propranolol, a beta-adrenergic antagonist, on blood flow in the coronary and other vascular fields. Am Heart J 73: 207–216PubMedGoogle Scholar
  363. Neely JR, Rovetto MJ, Oram JF (1972) Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 15: 289–329PubMedGoogle Scholar
  364. Nelson RR, Gobel FL, Jorgensen CR, Wang K, Wang Y, Taylor HL (1974) Hemodynamic predictors of myocardial oxygen consumption during static and dynamic exercise. Circulation 50: 1179–1189PubMedGoogle Scholar
  365. Nestel PJ (1966) Evaluation of propranolol (Inderal) in the treatment of angina pectoris. Med J Aust 2: 1274–1276PubMedGoogle Scholar
  366. Neuvonen PJ, Elonen E, Tanskanen A, Tuomilehto J (1982) Sotalol prolongation of the QTc interval in hypertensive patients. Clin Pharmacol Ther 32 (l): 25–32PubMedGoogle Scholar
  367. Nicotero J A, Beamer V, Moutsos SE, Shapiro P (1968) Effects of propranolol on pressor responses to noxious stimuli in hypertensive patients. Am J Cardiol 22: 657–666PubMedGoogle Scholar
  368. Nies AS, Shand DG (1975) Clinical Pharmacology of propranolol. Circulation 52: 6–15PubMedGoogle Scholar
  369. Nilsson A, Hansson B-G, Hokfelt B (1978) Effect of metoprolol on blood glycerol, free fatty acids, triglycerides and glucose in relation to plasma catecholamines in hypertensive patients at rest and following submaximal work. Eur J Clin Pharmacol 13: 5–8PubMedGoogle Scholar
  370. Norris RM, Sammel NL, Clarke ED, Brandt PWT (1980) Treatment of acute myocardial infarction with propranolol. Br Heart J 43: 617–622PubMedGoogle Scholar
  371. Norwegian Multicenter Study Group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801–807Google Scholar
  372. Nyberg G (1977) Blood pressure and heart rate during sustained handgrip in hypertensive patients taking placebo, a nonselective beta-blocker (propranolol) and a selective betablocker (metoprolol). Curr Ther Res 22: 828–838Google Scholar
  373. Nyberg G (1979) Effect of beta-adrenergic blockade on haemodynamic responses to dynamic and isometric exercise in angina pectoris. Eur J Clin Pharmacol 15: 381–388PubMedGoogle Scholar
  374. Nyberg G, Berglund G (1982) Effects of labetalol and propranolol on the peripheral circulation in hypertensive patients. Acta Med Scand [Suppl] 665: 93–101Google Scholar
  375. Nyberg G, Graham RM, Stokes GS (1977) The effect of mental arithmetic in normotensive and hypertensive subjects and its modification by beta-adrenoceptor blockade. Br J Clin Pharmacol 4: 469–474PubMedGoogle Scholar
  376. Obeid A, Spear R, Mookherjee S, Warner R, Eich R (1976) The effects of propranolol on myocardial energy stores during myocardial ischaemia in dogs. Circulation 54 [Suppl 2]: 159Google Scholar
  377. Odenthal K-P (1983) Zur Pharmakologie von Carteolol. Drug Res 331 (2 a): 281–285Google Scholar
  378. Oh VM, Kaye CM, Warrington SJ, Taylor EA, Wadsworth J (1978) Studies of cardioselectivity and partial agonist activity in beta adrenoceptor blockade comparing effects on heart rate and peak expiratory flow rate during exercise. Br J Clin Pharmacol 5: 107–120PubMedGoogle Scholar
  379. Ohlsson O, Lindell S-E (1981) The effects of pindolol and prazosin on hand blood flow in patients with cold extremities and on treatment with beta-blockers. Acta Med Scand 210: 217–219PubMedGoogle Scholar
  380. Ohnhaus EE, Nuesch E, Meier J, Kalberer F (1974) Pharmacokinetics of unlabelled and 14-C labelled pindolol in uraemia. Eur J Clin Pharmacol 7: 25–29PubMedGoogle Scholar
  381. Olesen J, Hougard K, Hertz M (1978) Isoproterenol and propranolol: ability to cross the blood-brain barrier and effects on cerebral circulation in man. Stroke 9: 344–349PubMedGoogle Scholar
  382. O’Malley K, O’Callaghan WG, Laher MS, McGarry K, O’Brien E (1983) Beta-adrenoceptor blocking drugs and renal blood flow with special reference to the elderly. Drugs 25 [Suppl 2]: 103–107Google Scholar
  383. Opie LH (1975) Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction: relation to myocardial ischaemia and infarct size. Am J Cardiol 36: 938–953PubMedGoogle Scholar
  384. Opie LH (1976) Propranolol and experimental myocardial infarction: substrate effects. Postgrad Med J 52 [Suppl 4]: 124–132PubMedGoogle Scholar
  385. Opie LH (1980) Drugs and the heart III. Calcium antagonists. Lancet 1: 806–810PubMedGoogle Scholar
  386. Opie LH, Thomas M (1976) Propranolol and experimental myocardial infarction: substrate effects. Postgrad Med J 52 [Suppl]: 124–133PubMedGoogle Scholar
  387. Oski FA, Miller LD, Delivoria-Papadopoulos M, Manchester JH, Shelburne JC (1972)Google Scholar
  388. Oxygen affinity in red cells: changes induced in vivo by propranolol. Science 175:1372–1373Google Scholar
  389. Page DL, Caulfield JB, Kastor JA, de Sanctis RW, Sanders CA (1971) Myocardial changes associated with cardiogenic shock. N Engl J Med 285: 133–137Google Scholar
  390. Pantano JA, Lee Y-C (1976) Abrupt propranolol withdrawal and myocardial contractility. Arch Intern Med 136: 867–871PubMedGoogle Scholar
  391. Parker JO, Di Giorgi S, West RO (1966) A hemodynamic study of acute coronary insufficiency precipitated by exercise. Am J Cardiol 17: 470–483PubMedGoogle Scholar
  392. Parker JO, West RO, Di Giorgi S (1971) The effect of nitroglycerin on coronary blood flow and the hemodynamic response to exercise in coronary artery disease. Am J Cardiol 27: 59–65PubMedGoogle Scholar
  393. Parker JO, Porter A, Parker JD (1982) Propranolol in angina pectoris: comparison of longacting and standard-formulation propranolol. Circulation 65: 1351–1355PubMedGoogle Scholar
  394. Parratt JR, Grayson J (1966) Myocardial vascular reactivity after beta-adrenergic blockade. Lancet 1: 338–340PubMedGoogle Scholar
  395. Pasotti C, Capra A, Fiorella G, Vibelli C, Chierichetti SM (1982) Effects of pindolol and metoprolol on plasma lipids and lipoproteins. Br J Clin Pharmacol 13 [Suppl 2]: 435S–439SPubMedGoogle Scholar
  396. Pasternack A, Porsti P, Poyhonen L (1982) Effects of pindolol and propranolol on renal function of patients with hypertension. Br J Clin Pharmacol 13 [Suppl 2]: 241S–244SPubMedGoogle Scholar
  397. Patrick JM, Pearson SB (1980) Beta-adrenoceptor blockade and ventilation in man. Br J Clin Pharmacol 10: 624–625PubMedGoogle Scholar
  398. Pedersen OL, Mikkelsen E, Nieseln JL, Christensen NJ (1979) Abrupt withdrawal of betablocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin. Eur J Clin Pharmacol 15: 215–217Google Scholar
  399. Pelides LJ, Reid DS, Thomas M, Shillingford JP (1972) Inhibition by ß-blockade of the ST segment elevation after acute myocardial infarction in man. Cardiovasc Res 6: 295–301PubMedGoogle Scholar
  400. Pendleton RG, Newman DJ, Sherman SS, Brann EG, Maya WE (1972) Effect of propranolol upon the haemoglobin-oxygen dissociation curve. J Pharmacol Exp Ther 180: 647–656PubMedGoogle Scholar
  401. Perks WH, Chatterjee SS, Croxson RS, Cruickshank JM (1978) Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction. Br J Clin Pharmacol 5: 101–106PubMedGoogle Scholar
  402. Peter T, Heng MK, Singh BN, Ambler P, Nisbet H, Elliott R, Norris RM (1978) Failure of high doses of propranolol to reduce experimental myocardial ischemic damage. Circulation 57: 534–540PubMedGoogle Scholar
  403. Phibbs CM, Van Tyn RA, Maclean LD (1961) Vulnerability of the dog heart to ventricular fibrillation: a comparative study of chronic ischaemia and three myocardial revascularization procedures. J Thorac Cardiovasc Surg 42: 228–235PubMedGoogle Scholar
  404. Phillips DK (1980) Chemistry of alpha- and beta-adrenoceptor agonists and antagonists. In: Szekeres L (ed) Adrenergic activators and inhibitors. Springer, Berlin Heidelberg New York, pp 3–61 (Handbook of experimental pharmacology, vol 54/1)Google Scholar
  405. Pine M, Favrot L, Smith S, McDonald K, Chidsey CA (1975) Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris. Circulation 52: 886–893PubMedGoogle Scholar
  406. Pitt B, Craven P (1970) Effect of propranolol on regional myocardial blood flow in ischaemia. Cardiovasc Res 4: 176–179PubMedGoogle Scholar
  407. Planz G, Planz R (1980) Influence of propranolol on catecholamine concentration in blood of normotensive man during physical exercise and dependence of the drug effect on dosage intervals. Arch Int Pharmacodyn Ther [Suppl] 1: 58–66Google Scholar
  408. Planz G, Planz R (1981) Dissociation between duration of plasma catecholamine and blood pressure responses to beta-adrenergic blockade in normotensive subjects during physical exercise. Eur J Clin Pharmacol 19: 83–88PubMedGoogle Scholar
  409. Podolsky S, Pattavina G (1973) Hyperosmolar non-ketotic diabetic coma: a complication of propranolol therapy. Metabolism 22: 685–693PubMedGoogle Scholar
  410. Podrid PJ, Lown B (1982) Pindolol for ventricular arrhythmia. Am Heart J 104 (2 Part II): 491–496PubMedGoogle Scholar
  411. Potter DE (1981) Effects of adrenergic activators and inhibitors of the endocrine system. In: Szekeres L (ed) Adrenergic activators and inhibitors. Springer, Berlin Heidelberg New York, pp 161–211 (Handbook of experimental pharmacology, vol 54/1)Google Scholar
  412. Powell CE, Slater IH (1958) Blocking of inhibitory adrenergic receptors by a dichloroanalog of isoproterenol. J Pharmacol Exp Ther 122: 480–488PubMedGoogle Scholar
  413. Prager G (1979) Angina pectoris: effective therapy once daily. J Int Med Res 7: 39–44PubMedGoogle Scholar
  414. Pratt CM, Welton DE, Squires WG, Kirby TE, Hartung GH, Miller RR (1981) Demonstration of training effect during chronic beta-adrenergic blockade in patients with coronary artery disease. Circulation 64 (6): 1125–1129PubMedGoogle Scholar
  415. Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105Google Scholar
  416. Prichard BNC (1964) Hypotensive action of pronethalol. Br Med J 1: 1227–1228PubMedGoogle Scholar
  417. Prichard BNC (1971) Beta-receptor antagonists in angina pectoris. Ann Clin Res 3: 344–352PubMedGoogle Scholar
  418. Prichard BNC (1974) Beta adrenergic receptor blocking drugs in angina pectoris. Drugs 7: 55–84PubMedGoogle Scholar
  419. Prichard BNC (1978) Beta-adrenergic receptor blockade in hypertension, past, present and future. Br J Clin Pharmacol 5: 379–399PubMedGoogle Scholar
  420. Prichard BNC (1982) Propranolol and beta-adrenergic receptor blocking drugs in the treatment of hypertension. Br J Clin Pharmacol 13: 51–60PubMedGoogle Scholar
  421. Prichard BNC (1983) Mechanisms of myocardial infarct prevention with beta-adrenergic blocking drugs. Drugs 25 [Suppl 2]: 295–302Google Scholar
  422. Prichard BNC, Boakes AJ (1977) The use of beta-adrenergic blocking drugs in hypertension: a review. Curr Med Res Opin 4 [Suppl 5]: 51–76Google Scholar
  423. Prichard BNC, Gillam PMS (1966) Propranolol in hypertension. Am J Cardiol 18: 387–391PubMedGoogle Scholar
  424. Prichard BNC, Gillam PMS (1969) Treatment of hypertension with propranolol. Br Med J 1: 7–16PubMedGoogle Scholar
  425. Prichard BNC, Gillam PMS (1971) Assessment of propranolol in angina pectoris. Clinical dose response curve and effect on electrocardiogram at rest and on exercise. Br Heart J 33: 473–480Google Scholar
  426. Prichard BNC, Ross EJ (1966) Use of propranolol in conjunction with alpha-receptor blocking drugs in phaeochromocytoma. Am J Cardiol 18: 394–398PubMedGoogle Scholar
  427. Prichard BNC, Vrhovac B (1975) Pharmacology of anti-anginal drugs. In: Harcus AW, Adamson L (eds) Arteries and veins. Churchill Livingston, London, pp 266–281Google Scholar
  428. Prichard BNC, Dickinson CJ, Alleyne GAO, Hurst P, Hill ID, Rosenheim ML, Laurence DR (1963) Effect of pronethalol in angina pectoris. Br Med J 2: 1226–1227PubMedGoogle Scholar
  429. Prichard BNC, Boakes AJ, Day GM (1971) Practolol in the treatment of hypertension. Postgrad Med J 47: 84–91Google Scholar
  430. Prichard BNC, Owens CWI, Tuckman J (1980) Clinical features of adrenergic agonists and antagonists. In: Szekeres L (ed) Adrenergic activators and inhibitors. Springer, Berlin Heidelberg New York, pp 559–697 (Handbook of experimental pharmacology, vol 54/ 2 )Google Scholar
  431. Prichard BNC, Walden RJ, Markiewicz A, Richards GA (1981) Beta-adrenergic blockade in ischaemic heart disease. Br J Clin Pract 12: 12–28Google Scholar
  432. Prichard BNC, Tomlinson B, Walden RJ, Bhattacharjee P (1983) The beta adrenergic blockade withdrawal phenomenon. J Cardiovasc Pharmacol 5: S56–S62PubMedGoogle Scholar
  433. Prinzmetal M, Kennamer R, Merliss R, Wada T, Bor N (1959) Angina pectoris. 1. A variant form of angina pectoris. Am J Med 27: 375–388Google Scholar
  434. Raftery EB, Denman AM (1973) Systemic lupus erythematosus syndrome induced by practolol. Br Med J 2: 452–455PubMedGoogle Scholar
  435. Rainwater J, Steele P, Kirch D, LeFree M, Jensen D, Vogel R (1982) Effect of propranolol on myocardial perfusion images and exercise ejection fraction in men with coronary artery disease. Circulation 65: 77–81PubMedGoogle Scholar
  436. Ranchod A, Keeton Gr, Benatar SR (1982) The effect of beta-blockers on ventilatory function in chronic bronchitis. S Afr Med J 62: 423–424Google Scholar
  437. Rangno RE, Langlois S (1982) Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. Am Heart J 104: 473–478PubMedGoogle Scholar
  438. Raptis S, Rosenthal J, Welzel D, Moulopoulos S (1981) Effects of cardioselective and noncardioselective beta-blockade on adrenaline-induced metabolic and cardiovascular responses in man. Eur J Clin Pharmacol 20: 17–22PubMedGoogle Scholar
  439. Rasmussen K, Andersen K, Wang H (1982) Atrial fibrillation induced by atenolol. Eur Heart J 3: 276–281PubMedGoogle Scholar
  440. Rasmussen MM, Remer KA, Kloner RA, Jennings RB (1977) Infarct size reduction by propranolol before and after coronary ligation in dogs. Circulation 56: 794–798PubMedGoogle Scholar
  441. Reeves PR, McAinsh J, Mcintosh DAD, Winrow MJ (1978) Metabolism of atenolol in man. Xenobiotica 8: 313–320PubMedGoogle Scholar
  442. Reeves RL, Sen SB, Summit NJ (1982) The effect of metoprolol and propranolol on pancreatic insulin release. Clin Pharmacol Ther 31: 262–263Google Scholar
  443. Regardh C-G, Johnsson G (1980) Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet 5: 557–569PubMedGoogle Scholar
  444. Reichert N, Shibolet S, Adar R, Gafni J (1975) Controlled trial of propranolol in intermittent claudication. Clin Pharmacol Ther 17: 612–615PubMedGoogle Scholar
  445. Religa A, Mueller HS, Evans R, Ayres SM (1973) Metabolic effect of propranolol on ischaemic tissue in human and experimental myocardial infarction. Clin Res 21: 954Google Scholar
  446. Rhabkin R, Stables OP, Levin NW, Suzman MM (1966) Prophylactic value of propranolol in angina pectoris. Am J Cardiol 18: 370–380Google Scholar
  447. Richards DA, Prichard BNC (1979) Clinical pharmacology of labetalol. Br J Clin Pharmacol 8: 89s–93sPubMedGoogle Scholar
  448. Richards DA, Prichard BNC, Boakes AJ, Tuckman J, Knight EJ (1977) Pharmacological basis for antihypertensive effects of intravenous labetalol. Br Heart J 39: 99–106PubMedGoogle Scholar
  449. Richtsmeier TE, Preston TA (1977) Drug management of stable angina pectoris. Postgrad Med J 62: 91–100Google Scholar
  450. Rieckert H, Kattwinkel W, Riechelmann H, Kuss A, Sierau R (1982) Peripheral haemodynamic effects of beta adrenoceptor blocking drugs with ISA or relative beta t- selectivity at rest and during physical exercise. Br J Clin Pharmacol 13: 227S–228SPubMedGoogle Scholar
  451. Riley AJ, Riley EJ (1981) The effect of labetalol and propranolol on the pressor response to sexual arousal in women. Br J Clin Pharmacol 12: 341–344PubMedGoogle Scholar
  452. Robertson RM, Wood AJJ, Vaughn WK, Robertson D (1982) Exacerbation of vasotonic angina pectoris by propranolol. Circulation 65: 281–285PubMedGoogle Scholar
  453. Robinson B, Pilkington T (1963) Effect of pronethalol in angina pectoris. Br Med J 2: 1227–1228Google Scholar
  454. Robinson BF (1967) Relation of heart rate and systolic blood pressure to the onset of pain in angina pectoris. Circulation 35: 1073–1083PubMedGoogle Scholar
  455. Robinson BF (1968) Mode of action of nitroglycerin in angina pectoris. Correlation between haemodynamic effects during exercise and provocation of pain. Br Heart J 30: 295–302PubMedGoogle Scholar
  456. Robinson BF (1971) The mode of action of beta-antagonists in angina pectoris. Postgrad Med J 47: 41–43Google Scholar
  457. Robinson BF, Wilson AG (1968) Effect on forearm arteries and veins of attenuation of the cardiac response to leg exercise. Clin Sci 35: 143–152PubMedGoogle Scholar
  458. Robson RD, Kaplan HR (1970) The cardiovascular pharmacology of bunolol, a new beta adrenergic blocking agent. J Pharmacol Exp Ther 175 (1): 157–167PubMedGoogle Scholar
  459. Robson RH, Vishwanath MC (1982) Nifedipine and beta-blockade as a cause of cardiac failure. Br Med J 284: 104Google Scholar
  460. Rodger CJ, Sheldon CD, Lerski RA, Livingstone WR (1976) Intermittent claudication complicating beta blockade. Br Med J 1: 1125PubMedGoogle Scholar
  461. Rose G (1982) Should every survivor of a heart attack be given a beta blocker? Part III: some conclusions. Br Med J 285: 39–40Google Scholar
  462. Ross PJ, Jones MK, John R (1980) Thyroid hormone levels after propranolol withdrawal. Clin Sci 58: 22 PGoogle Scholar
  463. Routledge PA, Shand DG (1979) Clinical pharmacokinetics of propranolol. Clin Pharmacokinet 4: 73–90PubMedGoogle Scholar
  464. Roy P, Day L, Sowton E (1975) Effect of new beta adrenergic blocking agent, atenolol ( Tenormin) on pain frequency, trinitrin consumption and exercise ability. Br Med J 3: 195–197Google Scholar
  465. Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE (1979) Selectivity of beta adrenoceptor antagonist drugs assessed by histamine provocation. Clin Pharmacol Ther 25: 536–540PubMedGoogle Scholar
  466. Russek HI (1968) Propranolol and isosorbide dinitrate synergism in angina pectoris. Am J Cardiol 21: 44–54PubMedGoogle Scholar
  467. Ryan JR, Lacorte W, Jain A, McMahon FG (1983) Response of diabetics treated with atenolol or propranolol to insulin-induced hypoglycaemia. Drugs 25 [Suppl 1]: 256–257Google Scholar
  468. Sadick NN, Tan ARH, Fletcher PJ, Morris J, Kelly DT (1982) A double-blind randomized trial of propranolol and verapamil in the treatment of effort angina. Circulation 66: 574–579PubMedGoogle Scholar
  469. Sainani GS, Mukherjee AK (1972) A double-blind trial of LB 46 (Visken) in angina pectoris. Indian Heart J 24 [Suppl 1]: 192–196PubMedGoogle Scholar
  470. Salvetti A, Arzili F, Pedrinelli R, Beggi P, Motolese M (1982) Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients. Eur J Clin Pharmacol 22: 197–201PubMedGoogle Scholar
  471. Sandler G, Clayton GA (1970) Clinical evaluation of practolol, a new cardioselective beta blocking agent in angina pectoris. Br Med J 2: 399–402PubMedGoogle Scholar
  472. Sandler G, Pistevos A (1972) Clinical evaluation of oxprenolol in angina pectoris. Br Heart J 34: 847–850PubMedGoogle Scholar
  473. Sarnoff SA, Braunwald E, Welch GH, Case RB, Stainsby WN, Macruz R (1958) Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension time index. Am J Physiol 192: 148–151PubMedGoogle Scholar
  474. Sarnoff SJ, Gilmore JP, Weisfeldt ML, Daggett WM, Mansfield PB (1965) Influence of norepinephrine on myocardial oxygen consumption under controlled hemodynamic conditions. Am J Cardiol 16: 217–226PubMedGoogle Scholar
  475. Sas M, Kovacs L (1981) Systemic pharmacology of adrenergic activators and inhibitors: Effects on the genital system. In: Szekeres L (ed) Adrenergic activators and inhibitors. Springer, Berlin Heidelberg New York, pp 213–242 (Handbook of experimental pharmacology, vol 54/2)Google Scholar
  476. Sassard J, Pozet N, McAinsh J, Legheand J, Zech P (1977) Pharmacokinetics of atenolol in patients with renal impairment. Eur J Clin Pharmacol 12: 175–180PubMedGoogle Scholar
  477. Schlierf G, Papenberg J, Raetzer H (1973) The effect of l-(Indo-4-yl-oxy)-3-isopropylamino-propran-2-ol (LB-46 Visken) on carbohydrate and lipid metabolism. Eur J Clin Pharmacol 5: 154–157Google Scholar
  478. Sehluter KJ, Aellig WH, Petersen K-G, Rieband H–CH, Wehrli A, Keip L (1982) The influence of beta adrenoceptor blocking drugs with and without intrinsic sympathomimetic activity on the hormonal responses to hypo- and hyperglycaemia. Br J Clin Pharmacol 13: 407S–417SGoogle Scholar
  479. Schrumpf JD, Sheps DS, Wolfson S, Aronson AL, Cohen LS (1977) Altered hemoglobin- oxygen affinity with long-term propranolol therapy in patients with coronary artery disease. Am J Cardiol 40: 76–82PubMedGoogle Scholar
  480. Schwartz JB, Jackson G, Kates RE, Harrison DC (1981) Long-term benefit of cardioselective beta blockade with once daily atenolol therapy in angina pectoris. Am Heart J 101: 380–385PubMedGoogle Scholar
  481. Scott ME, Balnave K (1980) Comparison of propranolol and Inderal LA in patients with angina. Ulster Med J 49: 79–84PubMedGoogle Scholar
  482. Sealey BJ, Lijiedal J, Ablad B, Nyberg G (1969) The effects of intravenous alprenolol on exercise tolerance in patients with angina pectoris. Pharmacologica Clinica 2: 46–50Google Scholar
  483. Sealey BJ, Lijiedal J, Nyberg G, Ablad B (1971) Acute effects of oral alprenolol on exercise tolerance in patients with angina pectoris. A dose response study. Br Heart J 33: 481–488Google Scholar
  484. Shah RR, Oates NS, Idle JR, Smith RL (1982) Beta-blockers and drug oxidation status. Lancet 1: 508–509Google Scholar
  485. Shand DG (1974 a) Individualisation of propranolol therapy. Med Clin North Am 58:1063–1069Google Scholar
  486. Shand DG (1974 b) Pharmacokinetic properties of beta adrenergic receptor blocking drugs. Drugs 7:39–47Google Scholar
  487. Shand DG (1976) The pharmacokinetics of propranolol: a review. Postgrad Med J 52: 22–25PubMedGoogle Scholar
  488. Shand DG, Rangno RE (1972) The disposition of propranolol. I Elimination during oral absorption in man. Pharmacology 7: 159–168Google Scholar
  489. Shand DG, Branch RA, Evans GH, Nies AS, Wilkinson GR (1973) The disposition of propranolol. VII. The effects of saturable hepatic tissue uptake on drug clearance by the perfused rat liver. Drug Metab Dispos 1: 679–686Google Scholar
  490. Shell WE, Sobel BE (1973) Deleterious effects of increased heart rate on infarct size in the conscious dog. Am J Cardiol 31: 474–479PubMedGoogle Scholar
  491. Shepherd AMM, Lin M-S, Keeton TK (1981) Hypoglycaemia - induced hypertension in a diabetic patient on metoprolol. Ann Intern Med 94: 357–358PubMedGoogle Scholar
  492. Shinebourne E, Flemming J, Hamer J (1967) Effects of beta-adrenergic blockade during exercise in hypertensive and ischaemic heart disease. Lancet 2: 1217–1220PubMedGoogle Scholar
  493. Shiroff RA, Mathis J, Zelis R, Schneck DW, Babb JD, Leaman DM, Hayes AH (1978) Propranolol rebound - a retrospective study. Am J Cardiol 41: 778–780PubMedGoogle Scholar
  494. Shumway NE, Johnson JA, Stish RJ (1957) The study of ventricular fibrilation by threshold determinations. J Thorac Surg 34: 643–653PubMedGoogle Scholar
  495. Silke B, Nelson GIC, Ahuja RC, Taylor SH (1982) Comparative haemodynamic dose response effects of propranolol and labetalol in coronary heart disease. Br Heart J 48: 364–371PubMedGoogle Scholar
  496. Simonsen S (1977) Effect of atenolol (ICI 66082) on coronary haemodynamics in man. Br Heart J 39: 1210–1216PubMedGoogle Scholar
  497. Singh BN, Jewitt DE (1974) Beta-adrenergic receptor blocking drugs in cardiac arrhythmias. Drugs 7: 426–461PubMedGoogle Scholar
  498. Singh BN, Vaughan Williams EM (1970) A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 39: 675–687PubMedGoogle Scholar
  499. Sklar J, Johnston D, Overlie P, Gerber JG, Brammell HL, Gal J, Nies AS (1982) The effects of a cardioselective (metoprolol) and a nonselective (propranolol) beta-adrenergic blocker on the response to dynamic exercise in normal men. Circulation 65: 894–899PubMedGoogle Scholar
  500. Slome R (1973) Withdrawal of propranolol and myocardial infarction. Lancet 1: 156PubMedGoogle Scholar
  501. Smith RS, Warren DJ (1982) Effect of beta-blocking drugs on peripheral blood flow in intermittent claudication. J Cardiovasc Pharmacol 4: 2–4PubMedGoogle Scholar
  502. Sondodi S, Agabiti-Rosel E, Fraser R, Leckie BJ, Morton JJ, Cumming AMM, Sood BP, Robertson JLS (1982) Response of the renin-angiotensin-aldosterone system to upright tilting and to intravenous frusemide: effect of prior metoprolol and propranolol. Br J Clin Pharmacol 13: 341–350Google Scholar
  503. Sonnenblick EH (1962) Implications of muscle mechanics in the heart. Fed Proc 21: 975–990PubMedGoogle Scholar
  504. Sonnenblick EH, Skelton CL (1971) Myocardial energetics: basic principles and clinical implications. N Engl J Med 285: 668–675PubMedGoogle Scholar
  505. Sonnenblick EH, Braunwald E, Williams JF, Glick G (1965) Effects of exercise in myocardial force - velocity relations in intact unaesthetised man: relative roles in change in heart rate, sympathetic activity and ventricular dimensions. J Clin Invest 44: 2051–2062PubMedGoogle Scholar
  506. Sonnenblick EH, Ross J, Braunwald E (1968) Oxygen consumption of the heart. Newer concepts of its multifactorial determination. Am J Cardiol 22: 328–336Google Scholar
  507. Sotaniemi EA, Pelkonen O, Arranto AJ, Sako S, Anttila M (1983) Effect of liver function on beta blocker kinetics. Drugs 25: 113–120Google Scholar
  508. Southall E, Nutt NR, Thomas RD (1982) Chronic stable angina: comparison of verapamil and propranolol. J Int Med Res 10: 361–366PubMedGoogle Scholar
  509. Sowton E, Smithen C (1971) Double-blind three-dose trial of oral alprenolol in angina pectoris. Br Heart J 33: 601–606PubMedGoogle Scholar
  510. Sowton E, Smithen C, Leaver D, Barr I (1971) Effect of practolol on exercise tolerance in patients with angina pectoris. Am J Med 51: 63–70PubMedGoogle Scholar
  511. Sponer G, Bartsch W, Strein K, Müller-Beckmann B (1982) The pharmacological profile of BM 14,190, a compound with beta-blocking and vasodilating properties. Naunyn-Schmiedebergs Arch Pharmacol 321 [Suppl R]: 21–81Google Scholar
  512. Sponer G, Voss E, Dietmann K (1981) Wirkung von IS-5-MN, Metipranolol und deren Kombination auf die provozierte Myocardischamie bei wachen Hunden. Med Welt 32 (14 a): 492–496PubMedGoogle Scholar
  513. Srivastava SC, Dewar HA, Newell DJ (1964) Double-blind trial of propranolol ( Inderal) in angina of effort. Br Med J 2: 724–725Google Scholar
  514. Steele P, Gold F (1982) Favorable effects of acebutolol on exercise performance and angina in men with coronary artery disease. Chest 1: 40–43Google Scholar
  515. Stephens J, Hayward R, Ead H, Adams L, Hamer J, Spurrell R (1978) Effects of selective and non selective beta-adrenergic blockade on coronary dynamics in man assessed by rapid atrial pacing. Br Heart J 40: 856–863PubMedGoogle Scholar
  516. Storstein-Spilker L (1970) The influence of the beta-receptor blocking agent LB-46, isosorbide-dinitrate and their combination on the exercise ECG. Cardiovasc Res 4: 298 pGoogle Scholar
  517. Svedmyr N, Malmberg R, Haggendal E (1970) The haemodynamic effects of sotalol (MJ 1999) and propranolol in man. Pharmacologica Clinica 2: 82–85Google Scholar
  518. Svendsen TL, Hartling O, Trap-Jensen J (1979) Immediate haemodynamic effects of propranolol, practolol, pindolol, atenolol and ICI 89,406 in healthy volunteers. Eur J Clin Pharmacol 15: 223–228PubMedGoogle Scholar
  519. Svendsen TL, Hartling OJ, Trap-Jensen J, McNair A, Bliddal J (1981) Adrenergic beta receptor blockade, haemodynamic importance of intrinsic sympathomimetic activity at rest. Clin Pharmacol Ther 29: 711–718PubMedGoogle Scholar
  520. Svensson A, Gudbrandsson T, Sivertsson R, Hansson L (1982) Haemodynamic effects of metoprolol and pindolol: a comparison in hypertensive patients. Br J Clin Pharmacol 13: 259S–267SPubMedGoogle Scholar
  521. Sybertz EJ, Baum T, Pula KK, Nelson S, Eynon E, Crawford S (1982) Studies on the mechanism of the acute antihypertensive and vasodilator actions of several ß-adrenoceptor antagonists. J Cardiovasc Pharmacol 4: 749–758PubMedGoogle Scholar
  522. Syvalahti E, Lammintausta R, Ilsalo E, Kanto J (1977) Cardioselective (metoprolol) and non-selective (propranolol) beta-blockade and glucose homeostasis. Ann Clin Res 9: 292–295PubMedGoogle Scholar
  523. Taggart P, Carruthers M (1972) Suppression by oxprenolol of adrenergic response to stress. Lancet 2: 256–258PubMedGoogle Scholar
  524. Taggart P, Carruthers M, Somerville W (1973) Electrocardiogram, plasma catecholamines and lipids and their modification by oxprenolol when speaking before an audience. Lancet 2: 341–346PubMedGoogle Scholar
  525. Takenaka T, Asano M, Berdeaux A, Giudicelli J-F (1982) Adrenoceptor blocking, hemodynamic and coronary effects of YM-09538, a new combined alpha- and beta-adrenoceptor blocking drug, in anaesthethized dogs. Europ J Pharmacol 85: 35–50Google Scholar
  526. Tarazi RC, Dustan HP (1972) Beta-adrenergic blockade in hypertension. Practical and theoretical implications of long term hemodynamic variations. Am J Cardiol 29: 633–640Google Scholar
  527. Taylor JA (1968) Hypotension after oral propranolol. Lancet 1: 532–533PubMedGoogle Scholar
  528. Taylor SH, Meeran MK ( 1973 b) The cardiovascular response to some environmental stresses and their modification by oxprenolol. In: Burley DM, Frier JH, Rondel RK, Taylor SH (eds) New perspectives in beta blockade. Ciba, Horsham, pp 293–306Google Scholar
  529. Taylor SH, Silke B, Lee PS, Hilal A (1982) Haemodynamic dose-response effects of intravenous beta-blocking drugs with different ancillary properties in patients with coronary heart disease. Eur Heart J 3: 564–569PubMedGoogle Scholar
  530. Textor SC, Fouad FM, Bravol EL, Tarazi RC, Vidt DG, Gifford RW (1982) Redistribution of cardiac output to the kidneys during oral nadolol administration. N Engl J Med 307: 601–604PubMedGoogle Scholar
  531. Thadani U, Parker JO (1979) Propranolol in angina pectoris: duration of improved exercise tolerance and circulatory effects after acute oral administration. Am J Cardiol 44: 118–125PubMedGoogle Scholar
  532. Thadani U, Parker JO (1980) Propranolol in angina pectoris: comparison of therapy given two and four times daily. Am J Cardiol 46: 117–123PubMedGoogle Scholar
  533. Thadani U, Sharma B, Meeran MK, Majid PA, Whitaker W, Taylor SH (1973) Comparison of adrenergic beta-receptor antagonists in angina pectoris. Br Med J 1: 138–142PubMedGoogle Scholar
  534. Thompson FD, Joekes AM, Foulkes DM (1972) Pharmacodynamics of propranolol in renal failure. Br Med J 2: 434–436PubMedGoogle Scholar
  535. Thulesius O, Gjores JE, Berlin E (1982) Vasodilating properties of beta adrenoceptor blockers with intrinsic sympathetic activity. Br J Clin Pharmacol 13: 229S–230SPubMedGoogle Scholar
  536. Tjandramaga TB, Thomas J, Verbeeck R, Verbesselt R, Verberckmoes R, De Schepper PJ (1976) The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol. Br J Clin Pharmacol 3: 259–265PubMedGoogle Scholar
  537. Toubes DB, Ferguson RK, Rice AJ, Aoki VS, Funk DC, Wilson WR (1970) Beta adrenergic blockade vs placebo in angina pectoris. Clin Res 18: 345Google Scholar
  538. Trap-Jensen J, Clausen JP, Noel I, Larsen OA, Krosgaard AR, Christensen JN (1976) The effects of beta adrenoceptor blockers on cardiac output, liver blood flow and skeletal muscle blood flow in hypertensive patients. Acta Physiol Scand [Suppl] 440: 30Google Scholar
  539. Trap-Jensen J, Carlsen JE, Svendsen TL, Christensen NJ (1979) Cardiovascular and adrenergic effects of cigarette smoking during immediate non-selective and selective beta adrenoceptor blockade in humans. Eur J Clin Invest 9: 181–183PubMedGoogle Scholar
  540. Trap-Jensen J, Carlsen JE, Hartling OJ, Svendsen TL, Tango M, Christensen NJ (1982) Beta adrenoceptor blockade and psychic stress in man. A comparison of the acute effects of labetalol, metoprolol, pindolol and propranolol on plasma levels of adrenaline and noradrenaline. Br J Clin Pharmacol 13: 391S–395SPubMedGoogle Scholar
  541. Tremberlay G, Biron P, Caille G, Robert P, Fontaine R (1981) Double-blind crossover trial of single versus twice-daily doses of acebutolol in angina. Curr Ther Res 29: 644–650Google Scholar
  542. Turi ZG, Braunwald E (1983) The use of beta-blockers after myocardial infarction. JAMA 249 (18): 12–16Google Scholar
  543. Turner GG, Nelson RR, Nordstrom LA, Diefenthal HC, Gobel FL (1978) Comparative effect of nadolol and propranolol on exercise tolerance in patients with angina pectoris. Br Heart J 40: 1361–1370PubMedGoogle Scholar
  544. Turner GG, Weir EK, Chesler E, Pierpont GL (1981) Reassessment of vasodilator therapy in angina: effects of oral isosorbide dinitrate and hydralazine on exercise tolerance in patients receiving propranolol. Am J Cardiol 47: 910–916PubMedGoogle Scholar
  545. Turner P (1983) Beta blockade and the human central nervous system. Drugs 25 [Suppl 2]: 262–264Google Scholar
  546. Ulrych M, Frolich ED, Dustan HP, Page IH (1968) Immediate haemodynamic effects of beta-adrenergic blockade with propranolol in normotensive and hypertensive man. Circulation 37: 411–416PubMedGoogle Scholar
  547. Vale JA, Jeffreys DB (1978) Peripheral gangrene complicating beta blockade. Lancet 1: 1216PubMedGoogle Scholar
  548. Vandenburg MJ, Conlon C, Ledingham JM (1981) A comparison of the effects of propranolol and oxprenolol on forearm blood flow and skin temperature. Br J Clin Pharmacol 11: 48 5–90Google Scholar
  549. Vandongen R, Davidson L, Beilin LJ, Barden AE (1981) Effect of beta adrenergic receptor blockade with propranolol on the response of plasma catecholamines and renin activity to upright tilting in normal subjects. Br J Clin Pharmacol 13: 369–374Google Scholar
  550. Van-Herwaarden CLA, Binkhorst RA, Fennis JFM, Van’T Laar A (1979) Effects of propranolol and metoprolol on haemodynamic and respiratory indices and on perceived exertion during exercise in hypertensive patients. Br Heart J 41: 99–105PubMedGoogle Scholar
  551. Vatner SF, Baig H, Manders WT, Ochs H, Pagani M (1977) Effects of propranolol on regional myocardial function, electograms and blood flow in conscious dogs with myocardial ischaemia. J Clin Invest 60: 353–360PubMedGoogle Scholar
  552. Velasco M, Vizcarrondo H, Urbina-Quintana A, Hernandez-Pieretti O (1982) A comparative study between pindolol and nadolol on systemic and cardiac hemodynamics in hypertensive patients. Curr Ther Res 32: 663–668Google Scholar
  553. Vestal RE, Wood AJJ, Branch RA, Shand DG, Wilkinson GR (1979) Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther 26: 8–15PubMedGoogle Scholar
  554. Vlachakis ND, Aledort L (1980) Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines and platelet aggregation. Am J Cardiol 45: 321–325PubMedGoogle Scholar
  555. Von Bahr C, Collste P, Frisk-Holmberg M, Haglund K, Jorfelt L, Orme M, Ostman J, Sjoqvist F (1976) Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade and plasma renin activity in essential hypertension. Clin Pharmacol Ther 20: 130–137Google Scholar
  556. von Mollendorff E, Huschka C, Schroter E, Abshagen U (1981) BM 12.434, a novel compound with vasodilating and ß-adrenoceptor blocking activities. Clin Sci 61: 477s–479sGoogle Scholar
  557. Waal-Manning HJ (1970) Comparative studies on the hypotensive effects of beta-adrenergic receptor blockade. In: Simpson FO (ed) Symposium on beta-adrenergic receptor blocking drugs. Ciba, Auckland, p 64Google Scholar
  558. Waal-Manning HJ (1976) Metabolic effects of beta adrenoceptor blockers. Drugs 11: 121–126PubMedGoogle Scholar
  559. Waal-Manning HJ (1979a) Can beta blockers be used in diabetic patients? Drugs 17: 157–160PubMedGoogle Scholar
  560. Waal-Manning HJ (1979 b) Atenolol and three nonselective beta blockers in hypertension. Clin Pharmacol Ther 25:8–18Google Scholar
  561. Waal-Manning HJ, Simpson FO (1971) Practolol treatment in asthmatics. Lancet 2: 1264–1265PubMedGoogle Scholar
  562. Wahlquist ML, Kaijser L, Lassers BW, Carslon LA (1973) Fatty acid as a determinant of myocardial substrate and oxygen metabolism in man at rest and during prolonged exercise. Acta Med Scand 193: 89–94Google Scholar
  563. Walden RJ, Bhattacharjee P, Tomlinson B, Cashin J, Graham BR, Prichard BNC (1982) The effect of intrinsic sympathomimetic activity on beta receptor responsiveness after beta adrenoceptor blockade withdrawal. Br J Clin Pharmacol 13: 359S–364SPubMedGoogle Scholar
  564. Walstad RA, Berg KJ, Wessel-Aas T, Nilsen OG (1982) Labetalol in the treatment of hypertension in patients with normal and impaired renal function. Acta Med Scand 665: 135–141Google Scholar
  565. Wan SH, Koda RT, Maronde RF (1979) Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br J Clin Pharmacol 7: 569–574PubMedGoogle Scholar
  566. Wasserman AJ, Proctor JD, Allen FJ, Kemp VE (1970) Human cardiovascular effects of alprenolol, a beta adrenergic blocker: haemodynamic, antiarrhythmic and antianginal. J Clin Pharmacol 10: 37–49Google Scholar
  567. Watkins J, Abott EC, Hensby CN, Webster J, Dollery CT (1980) Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin. Br Med J 281: 702–705PubMedGoogle Scholar
  568. Watson RDS, Eriksson B-M, Hamilton CA, Reid JL, Stallard TJ, Littler WA (1980) Effects of chronic beta-adrenoceptor antagonism on plasma catecholamines and blood pressure in hypertension. J Cardiovasc Pharmacol 2: 725–738PubMedGoogle Scholar
  569. Wayne V, Harper R, Laufer E, Federman J, Anderson S, Pitt A (1982) Adverse interaction between oral beta adrenergic blocking drugs and verapamil. Aust NZ J Med 12: 312Google Scholar
  570. Westerlund A (1982) Atenolol and timolol. N Engl J Med 307: 1343–1344Google Scholar
  571. Wiener L, Dwyer EM, Cox JW (1969) Hemodynamic effects of nitroglycerin, propranolol, and their combination in coronary heart disease. Circulation 39: 623–631PubMedGoogle Scholar
  572. Wilcox RG, Hampton JR (1982) Comparison between atenolol and nadolol in essential hypertension at rest and on exercise. Br J Clin Pharmacol 13: 841–846PubMedGoogle Scholar
  573. Wilcox RG, Roland JM, Banks DC, Hampton JR, Mitchell JRA (1980) Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. Br Med J 281: 885–888Google Scholar
  574. Wiles WJ, Peduzzi PN, Hammond G (1977) Preoperative predictors of operative mortality for coronary by-pass in patients with unstable angina pectoris. Am J Cardiol 39: 939–943PubMedGoogle Scholar
  575. Wilhelmsen L, Wedel H, Tibblin G (1973) Multivariate analysis of risk factors for coronary heart disease. Circulation 48: 950–958PubMedGoogle Scholar
  576. Wilhelmsson C, Vedin J A, Wilhelmsen L, Tibblin G and Werko L (1974) Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Lancet 2: 1157–1160PubMedGoogle Scholar
  577. Williams LT, Lefkowitz RJ (1978) Receptor binding studies in adrenergic pharmacology. Raven, New YorkGoogle Scholar
  578. Wilson AG, Brooke OG, Lloyd HF, Robinson BF (1969) Mechanism of action of betaadrenergic receptor blocking agents in angina pectoris; comparison of action of propranolol with dexpropranolol and practolol. Br Med J 4: 399–401PubMedGoogle Scholar
  579. Winer N, Chokshi DS, Yoon MS, Freedman AD (1969) Adrenergic receptor mediation of renin secretion. J Clin Endocrinol Met 29: 1168–1175Google Scholar
  580. Wiseman RA (1971) Practolol-accumulated data on unwanted effects. Postgrad Med J 47: 68–71Google Scholar
  581. Wolfson S, Gorlin R (1969) Cardiovascular pharmacology of propranolol in man. Circulation 40: 501–511PubMedGoogle Scholar
  582. Wolfson S, Heinle RA, Herman MN, Kemp HG, Sullivan JM, Gorlin R (1966) Propranolol in angina pectoris. Am J Cardiol 18: 345–353PubMedGoogle Scholar
  583. Woods KL, Linton SP, Kendall MJ, Faragher EB, Grieve RJ (1979) Exercise responses of healthy subjects in the evaluation of cardioselectivity of beta blockers. Eur J Clin Pharmacol 15: 229–233PubMedGoogle Scholar
  584. Wray R, Sutcliffe SB J (1972) Propranolol induced hypoglycaemia and myocardial infarction. Br Med J 2: 592PubMedGoogle Scholar
  585. Wright AD, Barber SG, Kendall MJ, Poole PH (1979) Beta-adrenoceptor blocking drugs and blood sugar control in diabetes mellitus. Br Med J 1: 159–161PubMedGoogle Scholar
  586. Wright P (1975) Untoward effects associated with practolol administration: oculumucocutaneous syndrome. Br Med J 1: 595–598PubMedGoogle Scholar
  587. Yasue H, Omote S, Takizawa A, Nagao M, Miwa K, Kato H, Tanaka S, Akiyama F (1978) Pathogenesis and treatment of angina pectoris at rest as seen from its response to various drugs. Jpn Circulation J 42: 1–11Google Scholar
  588. Yitibasi O, Nalbantgil I (1970) Essai d’un nouveau beta-bloquer le LB 46, dans le traitement de Pangine de poitrine. Praxis 59: 1218–1221Google Scholar
  589. Yusuf S, Ramsdale D, Peto R, Furse L, Bennett D, Bray C, Sleight P (1980) Early intravenous atenolol in suspected acute myocardial infarction. Lancet 2: 273–276PubMedGoogle Scholar
  590. Yusuf S, Rossi P, Ramsdale D, Peto R, Furse L, Motwani R, Parish S, Gray R, Bennett D, Bray C, Sleight P (1983) Reduction in infarct size, arrhythmias, chest pain and morbidity by early intravenous beta-blockade in suspected acute myocardial infarction. Drugs 25 [Suppl 2]: 303–307Google Scholar
  591. Zacharias FJ, Co wen KJ, Vickers J, Wall BG (1972) Propranolol in hypertension. A study of long term therapy 1964–1970. Am Heart J 83: 755–761PubMedGoogle Scholar
  592. Zaman R, Kendall MJ (1982) The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide. Br J Clin Pharmacol 13: 507–512PubMedGoogle Scholar
  593. Zito RA, Cassell I, Cunningham M, Gradman AH, Ross AM, Zaret BL (1980) High dose propranolol in the treatment of angina pectoris: relationship of dose to blood levels and hemodynamic consequences. Yale J Biol Med 53: 173–179PubMedGoogle Scholar
  594. Zsoter TT, Beanlands DS (1969) Propranolol in angina pectoris. Arch Intern Med 124: 584–587PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • B. N. C. Prichard

There are no affiliations available

Personalised recommendations